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dependent on the pituitary-specific transcription factor, POU1F1. While POU1F1 is expressed in both cell
types, and plays a direct role in the activation of both the Gh and Prl genes, GH expression is restricted to
somatotropes and PRL expression is restricted to lactotropes. These observations imply the existence of
additional, cell type-enriched factors, that contribute to the somatotrope and lactotrope cell identities. Here,
we use transgenic mouse models to facilitate sorting of somatotrope and lactotrope populations based on the
expression of fluorescent markers expressed under Gh and Prl gene transcriptional controls. The
transcriptomic analyses reveal a concordance of gene expression profiles in the two populations. The limited
number of mRNAs that are selectively enriched in each of the two populations includes a set of transcription
factors. A subset of these factors may have roles in pituitary lineage divergence, and/or in regulating
expression of cell-type specific genes after differentiation. Four of these factors were validated for lineage
enrichment at the level of protein expression, two somatotrope-enriched and two lactotrope-enriched. Three
of these four factors were shown to have corresponding activities in appropriate enhancement or repression of
landmark somatotrope or lactotrope genes in a pituitary-derived cell culture model system. Conditional
inactivation of the genes encoding these factors in mice revealed that two of these transcription factors impact
the expression of landmark hormone genes and alter cell phenotypes in primary murine pituitary. Subsequent
mechanistic studies revealed that these two factors act on their target genes either through a direct binding at
the target promoter and release of paused Pol II complexes, or through indirect mechanism(s). The functions
of these two factors are further remarkable in how they maintain hormone expression in the lactotrope and
somatotrope lineages; one serves to enhance landmark Prl gene expression in lactotropes while the second
serves to reciprocally repress expression of the Prl gene in somatotropes. In conclusion, these studies identify
novel regulators of the somatotropes and lactotropes, explore their mechanisms of action, and establish a
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ABSTRACT 
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF 
NOVEL DETERMINANTS OF THE SOMATOTROPE AND 
LACTOROPE LINEAGES IN THE ANTERIOR PITUITARY  
Michael T. Peel 
Stephen A. Liebhaber 
 
 The differentiation of the hormone-producing cell lineages of the anterior 
pituitary represents an informative model of mammalian cell fate determination. 
The generation and maintenance of two of these lineages, the growth hormone 
(GH) producing somatotropes and the prolactin (PRL) producing lactotropes, are 
dependent on the pituitary-specific transcription factor, POU1F1. While POU1F1 
is expressed in both cell types, and plays a direct role in the activation of both the 
Gh and Prl genes, GH expression is restricted to somatotropes and PRL 
expression is restricted to lactotropes. These observations imply the existence of 
additional, cell type-enriched factors, that contribute to the somatotrope and 
lactotrope cell identities. Here, we use transgenic mouse models to facilitate 
sorting of somatotrope and lactotrope populations based on the expression of 
fluorescent markers expressed under Gh and Prl gene transcriptional controls. 
The transcriptomic analyses reveal a concordance of gene expression profiles in 
the two populations. The limited number of mRNAs that are selectively enriched 
in each of the two populations includes a set of transcription factors. A subset of 
vii 
 
these factors may have roles in pituitary lineage divergence, and/or in regulating 
expression of cell-type specific genes after differentiation. Four of these factors 
were validated for lineage enrichment at the level of protein expression, two 
somatotrope-enriched and two lactotrope-enriched. Three of these four factors 
were shown to have corresponding activities in appropriate enhancement or 
repression of landmark somatotrope or lactotrope genes in a pituitary-derived cell 
culture model system. Conditional inactivation of the genes encoding these 
factors in mice revealed that two of these transcription factors impact the 
expression of landmark hormone genes and alter cell phenotypes in primary 
murine pituitary. Subsequent mechanistic studies revealed that these two factors 
act on their target genes either through a direct binding at the target promoter 
and release of paused Pol II complexes, or through indirect mechanism(s). The 
functions of these two factors are further remarkable in how they maintain 
hormone expression in the lactotrope and somatotrope lineages; one serves to 
enhance landmark Prl gene expression in lactotropes while the second serves to 
reciprocally repress expression of the Prl gene in somatotropes. In conclusion, 
these studies identify novel regulators of the somatotropes and lactotropes, 
explore their mechanisms of action, and establish a useful database for further 
study of these lineages in the anterior pituitary. 
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The abilities to preserve homeostasis and to react to physiological stimuli 
are among the most fundamental processes to life. In animals, entire organ 
systems are dedicated to regulating and maintaining these processes throughout 
the body, and many of these systems interact with each other dynamically. The 
endocrine system is a key component of this intricate network of regulation, 
signaling to a wide array of organs within the body through signaling molecules 
known as hormones. A central regulator of the endocrine system is the pituitary 
gland1. The pituitary gland is a small endocrine gland located at the base of the 
brain sometimes referred to as the “master gland” due to its central role in 
regulating a broad range of downstream endocrine functions. The pituitary is 
divided into two lobes: a posterior lobe and an intermediate/anterior lobe. Each of 
these lobes responds to physiological signals received from the hypothalamus, 
and secretes the appropriate hormone into the bloodstream in response to these 
signals1,2. Despite its small size, the pituitary produces a broad and diverse set of 
hormones, which regulate processes as varied as somatic growth, carbohydrate 
metabolism, reproduction, lactation, stress response, and skin pigmentation. 
Conventional understanding of the pituitary states that each of the pituitary 
hormones is produced and secreted by a dedicated cell type within the gland1,2. 
Thus, pituitary cells are not a singular cell type, but rather a set of multiple cell 
types occupying the same gland, each receiving specific signals from the 
hypothalamus and secreting their respective hormones in response. Within the 
anterior lobe of the pituitary, which produces the highest number of hormones of 
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the lobes, all of the cell types arise from a common developmental origin1,2 (Fig. 
1).  
The development of the pituitary is most clearly defined in the mouse. At 
e9.5, the oral ectoderm begins to invaginate in response to BMP4 expressed by 
the nearby diencephalon, forming an invagination known as Rathke’s pouch2. 
Within Rathke’s pouch, Gli family transcription factors, namely Gli1 and Gli2, are 
crucial regulators of early pituitary development, and deletion of Gli1 and Gli2 
causes a complete failure of the pituitary to develop in mice3. The Gli family of 
transcription factors is a component of the hedgehog (HH) signaling pathway. 
Pituitary development requires Sonic Hedgehog (Shh) expression, as inhibition of 
Shh prevents Rathke’s pouch from growing and prevents the development of all 
lineages of the endocrine cells of the anterior pituitary4. At approximately e11, the 
cells of Rathke’s pouch begin to express a cascade of transcription factors such 
as Lhx3, Pitx1, and Pitx21,2,5 , that guide development of endocrine cells within 
the developing pituitary. Many stages of anterior pituitary development remain 
incompletely understood, and there is conflicting information about the origin of 
some cell lineages. However, it is commonly agreed that after e12.5, sets of 
transcription factors drive development of the various endocrine cell lineages of 
the anterior pituitary from the common precursor cells of Rathke’s pouch1,2.  
The most abundant cells in the anterior pituitary are those that belong to 
the so-called “Pou1f1 lineages.6” The Pou1f1 lineages comprise three cell types 
within the anterior pituitary that all require the expression of the pituitary-specific 
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POU domain transcription factor, Pou1f1, for their development and for their 
continued function in the adult pituitary. These cell types, the thyrotropes, 
lactotropes, and somatotropes, produce thyroid stimulating hormone, prolactin, 
and growth hormone, respectively7-9. Both mice and humans with mutations in 
the Pou1f1 gene are characterized by a deficiency of growth hormone, prolactin, 
and thyroid stimulating hormone, highlighting that the differentiation and 
expansion of all three of these cell lineages share a common reliance on the 
actions of Pou1f110,11.   
Somatotropes and lactotropes are linked by a particularly close 
developmental relationship that remains incompletely understood1. Pou1f1 
expression is first detected in the mouse at e13.5, following activation via an 
unknown mechanism by the transcription factor Prop1 which is initially expressed 
at e10 2. The subsequent activation of growth hormone (GH) expression can be 
detected in the developing pituitary starting at e15.5 2. Prolactin (PRL) becomes 
detectable at e16.5, and many PRL positive cells also express GH at this stage 
in development, though the amount of these so called “somatolactotropes” varies 
across different species1,12,13. These somatolactotrope cells are postulated to 
resolve into somatotropes and lactotropes shortly after their appearance at 
e16.5, with somatolactotropes constituting only ~1% of all cells in the adult 
anterior pituitary14.  
Lineage tracing studies have examined the developmental relationship 
between somatolactotropes, somatotropes, and lactotropes. The findings of 
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these lineage tracing studies, carried out by a variety of approaches, are   
complex. Expression of various reporters under the control of Gh regulatory 
elements in mice indicates that a subset of lactotropes originate from cells that at 
one point in their development expressed Gh, though estimates of the 
percentage of lactotropes with Gh+ origins varies widely from 10% to nearly all 
lactotropes15-17. These data suggest that two sub-populations of lactotrope cells 
may exist: a population that derives from a Gh expressing progenitor, and a 
second population that originates independently of Gh expressing cells. 
Reciprocal lineage tracing studies using reporters under the regulation of Prl 
elements have found that somatotrope cells do not have a Prl+ developmental 
origin. These data thus suggest that lactotropes may be able to arise from 
somatotropes, but not vice versa18,19. Studies in which the lineage tracing was 
performed by targeted ablation of lactotrope cells in adult mice frequently note an 
increase in GH+/PRL+ somatolactotropes during the recovery period, raising the 
possibility of somatolactotrope cells being a transitional state in a one-way trans-
differentiation between somatotropes and lactotropes rather than a precursor to 
both somatotropes and lactotropes19,20. In conclusion, while the exact role of the 
somatolactotrope cells remains unclear, it is clear that the somatotrope and 
lactotrope cells have a complex and close relationship.  
As previously noted, the somatotrope and lactotrope cells both require 
expression of the pituitary-specific transcription factor, Pou1f1, for their 
differentiation and expansion8. However, the role of Pou1f1 in these cells extends 
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beyond the development of the two lineages. POU1F1 binds directly to the Gh 
and Prl promoters in terminally differentiated somatotropes and lactotropes and 
is the only clearly defined activator of both genes21. The paradox between the 
observation that POU1F1 activates both the Gh and the Prl genes, and yet the 
somatotropes and lactotropes exclusively express GH and PRL, respectively, 
forms the central issue that this thesis project seeks to address. The fundamental 
hypothesis of this study is that additional transcription factors are present in the 
somatotrope and lactotrope lineages that in some manner work in conjunction 
with POU1F1 activities so that GH and PRL are specifically expressed in their 
respective cell lineages.  
Despite an understanding of how the somatotrope and lactotrope cells 
function at the level of hormone secretion (i.e., knowledge of which physiological 
cues and signals from the hypothalamus act on these cells), there are only a few 
additional (non-hormonal) genes that are known to be expressed specifically in 
the somatotropes or the lactotropes. Several of these genes express key cell 
surface receptors that control the expression and/or secretion of each 
hormone22,23. Additionally, previous studies have suggested that factors such as 
the ubiquitously-expressed repressor NCoR, and the transcription (co)factor 
LSD1 have opposing functions in the somatotropes and lactotrope cells24,25. 
Unfortunately, such identification of potential regulators of each lineage originate 
primarily from a single laboratory, have not been followed up or confirmed since 
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publication, fail to investigate functional impacts of their identified factors, are 
based primarily on cell line models, and lack validation in animal models24,26,27.  
In the following studies, we use a variety of orthogonal methods to gain 
insight into the crucial differences between the somatotropes and lactotropes at 
the level of gene expression. These studies focus primarily on the identification of 
novel regulators of both the somatotrope and lactotrope lineages. The results of 
these studies are likely to further our understanding of how these two cell types 
are able to maintain separate cell identities and selectively express their 
corresponding hormone products.  
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Figures and legends 
 
Figure 1. Current standard model of anterior pituitary differentiation in 
mouse. The cells of the anterior pituitary begin to differentiate from oral ectoderm 
at e8.5. Expression of the transcription factor Prop1 is a precursor to Pou1f1 
expression, and Pou1f1 is expressed in all cells encompassed by the bracket. 
The somatolactotrope precursor cell arises at e16.5 and differentiates into both 
somatotropes and lactotropes (highlighted in blue). The existence of the 
hormone-negative Pou1f1+ cell and the triple positive cell type is hypothetical 
(dashed lines) and is based on a Tag-capture study from our lab28. This figure is 
adapted from2. 
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CHAPTER II: IDENTIFICATION AND VALIDATION OF 
NOVEL SOMATOTROPE AND LACTOTROPE ENRICHED 
TRANSCRIPTION FACTORS 
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Introduction 
The differentiation of multiple cell types from a common precursor cell and 
the subsequent maintenance of distinct cell identities throughout adult life are 
processes central to most developmental systems29,30. A key question in such 
processes is how a common precursor cell can give rise to multiple cell types 
with discrete transcriptomic profiles. Cell types differentiating from a common 
precursor cell must not only activate transcription of genes necessary for the 
appropriate cell fate, but also repress/silence expression of genes that drive 
alternate cell identities. The coordination of these opposing regulatory processes 
is likely to reflect cell type specific mechanisms of transcriptional control. In 
addition, terminally differentiated cells must be subsequently maintained in the 
differentiated state throughout adult life. This necessitates sustained 
mechanisms and pathways for maintaining cell fate. The establishment and 
maintenance of cell fate may be regulated by transcription factors that are 
expressed during development and/or by factors that are induced and sustained 
during the lifespan of the organism31,32.  
The anterior pituitary is an ideal system for studying mechanisms of 
lineage establishment and maintenance due to the terminal differentiation and 
divergence of somatotropes and lactotropes. In mice, the pituitary-specific master 
regulatory transcription factor, POU1F1, is expressed in a subset of developing 
pituitary cells beginning at e13.52,33,34. According to a frequently cited model, 
these POU1F1+ cells differentiate into the thyroid stimulating hormone (TSH) 
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producing thyrotropes and the GH/PRL dual expressing somatolactotropes at 
e16.52,35 (Fig. 1). The somatolactotrope precursor then gives rise to the 
terminally differentiated somatotropes and lactotropes, which produce high levels 
of GH and PRL protein, respectively36. While small populations of 
somatolactotropes remain present in the pituitaries of adult mice, comprising 
approximately 1-2% of all cells in the anterior pituitary, their function remains 
poorly understood (See Chapter I for more details on somatolactotropes)13,37. 
Thus, there is a need to better understand the mechanisms that regulate the 
differentiation, expansion, and functions of the somatotrope and lactotrope 
populations.  
Despite some questions about the pathway of somatotrope and lactotrope 
divergence and terminal differentiation, all current models of this pathway agree 
that expression of Pou1f1 is essential to the establishment of both populations of 
cells and that the somatotrope and lactotrope cells are closely related. In addition 
to being a master regulator of the somatotrope and lactotrope lineages, POU1F1 
is also a direct activator of both the Gh and Prl genes, and remains expressed in 
terminally differentiated somatotropes and lactotropes, driving robust hormone 
expression throughout adult life9,21,38,39. Despite this expression of Pou1f1 in both 
cell types, the expression of the GH and PRL proteins remains primarily 
restricted to the somatotropes and lactotropes, respectively2,40. This observation 
suggests the existence of unknown somatotrope and lactotrope specific factors 
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that contribute to the divergence and corresponding specificity of gene 
expression in the two lineages.  
Several genes have been previously identified as lineage-enriched and 
essential to the ability of somatotropes and lactotropes to respond to the 
appropriate physiological signals to secrete their respective hormones. The 
growth hormone releasing hormone receptor, GHRHR, and the dopamine 
receptor DRD2 are examples of known receptors expressed on the surfaces of 
somatotrope and lactotrope cells, respectively. These cell surface receptors 
regulate the expression and secretion of GH and PRL in response to 
physiological cues that trigger signaling from the hypothalamus23,41,42. However, 
the currently known sets of somatotrope and lactotrope specific genes are 
insufficient to adequately explain the mechanism(s) by which the somatotrope 
and lactotrope cell identities are established and maintained. Importantly, and 
central to this thesis, is the fact that POU1F1 remains the only known 
transcription factor that has been reproducibly demonstrated to directly activate 
the Gh and Prl genes26,43; some potential activators and repressors have been 
suggested but not validated or definitively explored (See Chapter I)24. Taken 
together, these observations suggest that there exists a set of currently 
unidentified transcription factors that contribute to the respective somatotrope 
and/or lactotrope expression profiles. The identification of these factors is 
essential to a detailed understanding of the function and pathology of these two 
predominant cell types within the anterior pituitary.  
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Here we have utilized a set of transgenic mouse lines to facilitate the 
isolation of primary somatotrope and lactotrope populations from the adult mouse 
pituitary. Transcriptomic profiling of these two cell populations reveals a 
noteworthy concordance in their respective transcriptomes. Despite this 
transcriptomic similarity, we were able to identify from this analysis approximately 
300 genes that are significantly enriched (Log2 fold change >2 and p-value 
<0.05) in each of the two cell populations. These enriched genes included a 
subset of transcription factors. Six of these transcription factors were selected for 
in-depth analysis based on their putative functions. Four of these factors were 
confirmed for selective enrichment in primary somatotrope and lactotrope cells at 
the level of protein expression. Our data establish a transcriptomic resource for 
analysis of somatotrope and lactotrope gene expression and cellular function, 
and identify a set of novel cell-type enriched transcription factors that have 
potential roles in regulating the expression of landmark hormone genes. 
Results 
Establishing the transcriptomes of flow sorted somatotropes and 
lactotropes. 
The goal of this work was to identify novel transcription factors involved in 
the maintenance of cell identity in the terminally differentiated somatotropes and 
lactotropes. This goal was approached by marking primary cell populations in the 
adult mouse pituitary with transgene-encoded fluorescent proteins. Somatotrope 
cells were tagged with a GFP reporter under the control of the human growth 
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hormone promoter and its upstream locus control region (LCR)44, while 
lactotrope cells were tagged by a DsRed reporter regulated by the rat Prl 
promoter and upstream sequences (Fig. 2A). These regulatory elements have 
been previously demonstrated as sufficient to define somatotrope and lactotrope-
specific expression in mice45,46. Modifications were made to the GH-GFP cosmid 
using conventional sub-cloning techniques to truncate the growth hormone signal 
peptide (see Methods), allowing accumulation of GFP in somatotrope cells 
rather than secretion, thus improving the GFP signal in this mouse line 
(Supplemental Figure 1). The somatotrope specificity of this modified Gh-GFP 
line was validated by immunofluorescence microscopy (Supplemental Figure 
2). 6-8 week old virgin female compound transgenic mice carrying the Gh-GFP 
and Prl-DsRed transgenes were generated for analysis. The use of compound 
transgenic mice permits the isolation of somatotropes and lactotropes from the 
same mouse pituitaries simultaneously, allowing the direct comparison of 
somatotropes and lactotropes with a minimization of experimental variables. The 
use of females in these studies ensured our ability to isolate appreciable 
numbers of lactotropes for subsequent analysis. These females were analyzed at  
6-8 weeks; at this point in “adult” life the pituitary has fully matured and 
established the full array of resident cell lineages47,48. 5-6 pituitaries were 
collected for each RNA-seq analysis, and these pituitaries were pooled and 
FACS sorted into GFP+ and DsRed+ populations (Fig. 2B). 
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The study was carried out in biological triplicate, beginning each 
independent study with a new set of compound transgenic mice. RNA was 
extracted from each of the two flow sorted cell populations and libraries were 
generated using low cell input methods (see Methods for more details). The 
RNA-seq data from these three biological replicates were then pooled and the 
composite transcriptome data set was used to establish the RNA profiles for the 
GFP and DsRed cell sorts. The use of a composite transcriptomic data set 
allowed for statistical analyses that aided the process of selecting genes of 
interest from the data set based on the robustness of their enrichment in each of 
the replicate samples. The enrichment of somatotropes or lactotropes in the flow 
sorted cell populations was confirmed by comparing the relative levels of anterior 
pituitary hormone gene expression in the GFP+ and DsRed+ populations to the 
expression of these hormone genes in total pituitaries from virgin female, age-
matched controls (Fig. 2C). These analyses included all hormone-encoding 
genes of the anterior pituitary, including pro-opiomelanocortin (Pomc), the beta 
subunits for thyroid stimulating hormone (Tshb), luteinizing hormone (Lhb), and 
follicle stimulating hormone (Fshb), as well as the shared heterodimerizing alpha 
subunit (Cga). Combined with Gh and Prl, these genes represent the full set of 
anterior pituitary hormones and serve as markers for each of the cell lineages of 
the anterior pituitary. Gh expression was enriched in the GFP+ samples while the 
expression of all other hormone genes was depleted as compared to total 
pituitary. Similarly, Prl expression was enriched in DsRed+ samples over the Prl 
expression observed in total pituitary. These data demonstrate that the described 
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FACS procedure yields cell pools that are highly enriched for the somatotrope 
and lactotrope cell populations.  
A second set of analyses of the transcriptomic data assessed the relative 
expression of sets of well-characterized marker genes that define the 
somatotrope and lactotrope lineages. A plot of three known markers for each cell 
type as well as five genes expected to be expressed at similar levels in both cell 
types (Fig. 3A) revealed that each of the somatotrope and lactotrope marker 
genes was appropriately enriched in its respective GFP+ or DsRed+ cell pool 
while genes known to be shared in the somatotrope and lactotrope lineages were 
expressed at approximately equal levels in both populations. GFP and DsRed 
reads were also appropriately enriched in each population, confirming proper 
FACS sorting by fluorescent reporter (Supplemental Table 1). Together, these 
data indicate that the transcriptomic data set is consistent with the assignment of 
somatotrope and lactotrope cell identities to the GFP+ and DsRed+ labeled 
populations, respectively2,16,22,49-51. 
The concordant transcriptomes of the flow sorted somatotropes and 
lactotropes reveal a limited subset of lineage-enriched transcription 
factors. 
Comparison of the transcriptomes of the flow sorted GFP+ and DsRed+ 
cell pools reveals a striking level of concordance in gene expression (Fig. 3B). 
The overall Pearson correlation value for somatotropes vs. lactotropes was 
calculated as 0.42. However, the expression of Gh and Prl in these cells is so 
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robust (note their extreme outlier positions on a log2 scale in Fig. 3B) that these 
two transcripts markedly skew the Pearson R value and distort the overall 
transcriptomic comparison. Removing Gh and Prl from the correlation 
calculations yields a Pearson R value of 0.94. The significance of these values is 
two-fold. First, the change from 0.42 to 0.94 observed in the Pearson value when 
Gh and Prl are excluded demonstrates the dominance of these two transcripts in 
the transcriptomes of the somatotropes and lactotropes, with Gh and Prl reads 
totaling approximately 25-33% of the mRNA reads in both cell types. Second, the 
Pearson value of 0.94 after exclusion of Gh and Prl highlights the overall 
similarity of the transcriptomes of these two cell types, except for their hormone 
expression levels. This overall similarity at the transcriptomic level is consistent 
with a close developmental relationship of these two cell types and suggests that 
the somatotrope and lactotrope identities are likely to be driven and maintained 
by a limited number of lineage-enriched factors2,20,52.  
A specific issue that could be directly addressed from these data was 
whether the structure of Pou1f1 in the two lineages might differ. The 
transcriptome data demonstrated that the structure of the Pou1f1 mRNA is 
identical in the two pools. These data effectively rule out a contribution by 
alternative splicing of the Pou1f1 transcript53 and generation of lineage-specific 
Pou1f1 isoforms to cell type specific functions of Pou1f1 (Fig. 3C). These 
findings further highlight the importance of additional factors in driving 
somatotrope and lactotrope specificity. 
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Genes that surpassed a threshold of a Log2 fold change of 2 (Fig. 3B, 
highlighted in red) were further filtered by significance (p-value <0.05) and 
expression level to remove genes that are expressed at low levels and not 
consistently enriched across all replicates. This differential expression analysis 
yielded approximately 300 lineage enriched genes for each cell type. Using gene 
ontology (GO) terms to guide the filtering of these 300 lineage enriched genes 
produced a list of 24 differentially expressed genes with annotated transcription 
factor activity (Fig. 3D). Thus, these transcriptomic analyses identified a set of 
lineage-enriched transcription factors that may be important to the distinct 
attributes of the somatotrope and lactotrope lineages.  
Validation of transcription factor differential expression in somatotropes 
and lactotropes by immunofluorescence analysis of primary pituitary cells. 
In order to maximize the effectiveness of downstream studies on the 
identified lineage-enriched transcription factors, we prioritized for further study a 
subset of six lineage-enriched transcription factors -- 3 enriched in somatotropes 
and 3 enriched in lactotropes-- that have functions reported in the literature that 
are consistent with a role that could be related to pituitary gene regulation. We 
next attempted to validate that each of the six transcription factors identified 
enriched at the level of mRNA expression was also enriched at the level of 
protein expression with the understanding that mRNA expression is not always 
paralleled by protein production. We also wanted to determine the site of 
accumulation of each of these proteins, as functional transcription factors would 
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be expected to accumulate in the nucleus in order to impart transcriptional 
controls.   
Wild type adult female mouse pituitaries were disaggregated and 
assessed by immunofluorescence microscopy (IF) for each of the six factors. 
This was done in parallel with immunostaining for GH and PRL proteins in order 
to mark somatotropes and lactotropes. The first factor to be studied was NUPR1, 
a somatotrope-enriched factor chosen based on its role in a defined pituitary cell 
differentiation process centered on the gonadotrope lineage43,54. NUPR1 was 
enriched in the nuclei of somatotrope (GH+) cells, consistent with the enrichment 
of the respective mRNA in the GFP+ cells (Fig. 4A). Of note, NUPR1, while 
enriched in somatotropes vs. lactotropes, was also detected in additional pituitary 
cells that are both GH and PRL negative. This observation is consistent with 
reports that NUPR1 plays a role in the development gonadotropes54.  
A second somatotrope-enriched factor, RXRG, was selected for study due 
to the stimulating effects of its ligand, retinoic acid, on growth hormone 
production, as well as on its reported heterodimerization with the thyroid 
hormone receptor, which is reported to bind at the Gh promoter55-58. RXRG 
protein was also observed to be enriched in the nuclei of somatotrope cells, 
identifying it as a gene of interest for further study (Fig. 4B). The third 
somatotrope candidate factor, PPARG, has been shown in previous studies to be 
frequently expressed in GH secreting pituitary adenomas, suggesting a role in 
regulating the somatotrope lineage59. Immunofluorescence microscopy of 
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PPARG protein revealed that it was enriched in somatotropes as expected (Fig. 
4C), but was also present in 48% of lactotropes (detailed cell counts for all 
immunofluorescence studies are available in Table 1). Therefore, while Pparg 
may have a role in the regulation of these lineages, we excluded Pparg from 
further study and focused on Nupr1 and Rxrg due to their more clearly defined 
somatotrope enrichment. These studies thus confirmed that 2 of the 3 identified 
somatotrope-enriched factors are appropriately expressed in primary 
somatotrope cells, and thus these factors were selected for further studies. 
IF studies were next carried out on the three transcription factors whose 
mRNAs were enriched in lactotropes. Among the candidate transcription factors 
selected from the lactotrope cell population, NR4A2 has been demonstrated to 
positively regulate transcription of the prolactin gene in extra-pituitary (lymphoid) 
tissue, making it a gene of interest for its potential role in the regulation of the 
lactotrope lineage60. The NR4A2 protein was enriched in the nuclei of lactotrope 
(PRL+) cells (Fig. 4D), consistent with transcriptomic data. POU4F1, a member 
of the POU family of transcription factors, was selected for study due to its role in 
stimulating aggressive proliferation of pituitary adenomas61, and on its multiple 
regulatory roles in development throughout the neuroendocrine system7,62. We 
observed that the POU4F1 protein was also enriched in the nuclei of lactotrope 
cells, suggesting a potential for regulating the lactotrope lineage (Fig. 4E). Lastly, 
TBX19 was selected for study because it is known to be crucial for pituitary 
development and establishment of cellular differentiation in the anterior lobe and 
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intermediate lobe in pituitary, with its primary known function being in regulating 
the corticotrope lineage where it has been reported to be specifically 
expressed63-65. Immunofluorescence microscopy revealed TBX19 protein in both 
somatotropes and lactotropes, as well as in additional cell types that were not 
further characterized (Fig. 4F). Thus, while Tbx19 might be of interest to the 
regulation of lactotropes, we chose to drop it from our initial studies.  
The IF studies identified four factors that were enriched in the nuclei of the 
appropriate cell types: Nupr1, Rxrg, Nr4a2, and Pou4f1.  Each of these four 
factors demonstrated robust cell type enrichment at the mRNA and protein 
levels, and demonstrated restriction to the nucleus. All of these observations are 
consistent with their identification as lineage-enriched transcription factors in our 
transcriptomic analyses. In conclusion, the immunofluorescence microscopy 
studies of these four transcription factors validated the RNA-seq data generated 
from primary somatotropes and lactotropes, and suggested that they may play a 
role in somatotrope vs. lactotrope differentiation and/or specification of cellular 
function. 
Discussion 
The establishment and maintenance of cell lineages within the anterior 
pituitary represents a robust model of cell type specification66,67. Delineating the 
controls of the relevant pathways is critical to understanding normal and 
pathologic pathways of pituitary functions as they relate to mammalian growth, 
reproduction, stress response and metabolic functions. Identification of these 
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pathways and their driving factors has the potential to provide novel targets for 
diagnosis and therapy of abnormalities in hormone expression and function. As 
an illustration of the potential benefits of improving understanding of these 
lineages, the majority of prolactin secreting adenomas (prolactinomas) can be 
treated medically rather than surgically by administration of dopamine agonists, 
which bind to the DRD2 receptor and selectively inhibit lactotrope proliferation 
and prolactin expression68. While this medical approach is widely employed in 
clinical practice, a subset of prolactinomas do not respond to such therapy, 
necessitating more invasive treatment due to the lack of known treatment targets 
beyond the dopamine receptor. This gap in therapeutic efficacy highlights the 
unmet need for better understanding these lineages and their underlying control 
pathways69,70.  
Extensive genetic studies in humans and mice have identified a number of 
transcription factors that are essential for pituitary development and function in 
the mammalian embryo. However, the identification and functional 
characterization of factors that drive specification of the two primary lineages in 
the anterior pituitary, the somatotropes and lactotropes, remains remarkably 
limited2,43. According to current models, these lineages are hypothesized to 
diverge from a common “somatolactotrope” precursor late in embryogenesis 
(Fig. 1)2, although there is some evidence that a subset of lactotropes emerge 
directly from somatotrope cells15. What is clear is that the pathways of cell 
expansion and terminal differentiation that generate and maintain both 
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somatotropes and lactotropes are dependent on the functions of the pituitary 
master regulatory transcription factor, POU1F1. Although both of these lineages 
depend on POU1F1 for their expansion and hormonal expression, it is evident 
that additional factors must be involved in driving their functional divergence. 
Factors identified in limited previous studies (see Chapter I) failed to exhibit 
evidence of differential expression in our transcriptome analyses, highlighting the 
challenges in selecting targets for further study without transcriptomic data for 
isolated cell populations. The identification of such factors has also been 
hampered in most studies due to their focus on the limited number of known 
marker proteins or their encoding mRNAs. Thus, substantial advances will 
depend on the use of more broad based discovery approaches. 
In the initial phase of this thesis project, we established and compared the 
transcriptomes of the somatotrope and lactotrope lineages isolated from the adult 
mouse pituitary. These transcriptomic databases were derived by RNA-seq 
analysis of cell populations isolated on the basis of fluorescent markers (GFP 
and DsRed) driven by the Gh or the Prl transcription regulatory elements. The 
validity of this approach was supported by a high level of enrichment of the 
expected hormone mRNAs in each RNA-seq data set (Fig. 2C) and by the 
enrichment of other known marker genes (Fig. 3A). Analysis of these data sets 
allowed us to arrive at several fundamental observations. First, the direct 
comparison of the transcriptomes of the two cell types, after removing Gh and Prl 
from the analysis, revealed a striking overall correlation (Pearson = 0.94; Fig. 
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3B). This high level of concordance affirms the close developmental and 
functional relationships of these two lineages. The second observation is that the 
two cell populations partially overlap in the expression of their key hormone 
genes, Gh and Prl. While we find that Gh mRNA is appropriately enriched in the 
GFP+ cell pool and Prl mRNA is appropriately enriched in the DsRed+ cell pool 
(Fig. 3A), there are appreciable levels of Gh mRNA in the lactotrope (DsRed+) 
population and a reciprocal representation of Prl mRNA in the somatotrope 
(GFP+) population (Fig. 2C). While it is likely that small amounts of cross-
contamination inherent in techniques such as FACS contribute in part to this 
result, these data are consistent with the established observations that both 
genes are activated by Pou1f1, which is expressed in both somatotropes and 
lactotropes, raising the possibility of a basal level of transcription of the reciprocal 
hormone in each lineage. This observation that a detectable amount of Gh and 
Prl mRNAs are produced in the reciprocal lineages supports a model in which 
somatotropes and lactotropes repress but do not entirely silence the Prl and Gh 
genes, respectively. The third observation is that, despite the overall similarities 
in the transcriptomes of the somatotropes and lactotropes noted above, a set of 
approximately 300 genes, including multiple transcription factors, is significantly 
enriched in each lineage. Taken together, these observations suggest that the 
transcriptomic differences between the somatotrope and lactotrope lineages are 
quite limited, yet clearly crucial; differential expression of a small set of genes is 
able to drive noteworthy differences in cell identity and function. 
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The transcriptome data generated in the present study provide insights 
into aspects of the somatotrope and lactotrope lineages beyond lineage-enriched 
transcription factors. While the scope of the present study centers on these 
transcription factors, other aspects of the transcriptomes of the somatotropes and 
lactotropes may be of interest for future studies. One post-transcriptional 
mechanism that has been hypothesized to contribute to differential regulation in 
the somatotrope and lactotrope lineages is alternative splicing of Pou1f1. There 
are two known isoforms of Pou1f1: the major isoform, known simply as Pou1f1, 
and the alternative isoform Pou1f1β, formed by alternative splicing extending the 
second exon, which has been previously suggested to have a repressive function 
in regulating gene expression in the POU1F1-dependent lineages of the 
pituitary53,71,72. Our data reveals that the levels of Pou1f1 mRNA and its exonic 
structure (Fig. 3C) are equivalent in the somatotrope and lactotrope populations. 
This observation supports the hypothesis that the divergence of lactotropes and 
somatotropes is based on the functions of a set of somatotrope and lactotrope 
specific factors that may work independently, or in conjunction with POU1F1, 
rather than differences in the levels or structure of POU1F1 itself.  
Further analysis of the genes that are enriched in somatotropes and 
lactotropes was performed. Enriched Gene Ontology (GO) terms were 
determined by running the Gene Ontology Consortium’s enrichment analysis tool 
on the approximately 300 statistically enriched genes in both somatotropes and 
lactotropes (Supplemental Tables 1 and 2, respectively). While many of the 
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enriched GO terms do not have obvious links to somatotrope/lactotrope function, 
“hormone activity” is a significantly enriched GO term, consistent with the primary 
function of these cell types. However, many of the genes included in the 
enrichment of this term are previously known genes such as Gh itself and Ghrhr. 
Thus, the utility of GO term analysis in identifying novel genes involved in the 
somatotrope and lactotrope lineages is limited due to the reliance of GO term 
analysis on existing knowledge about the roles of many genes, and the narrow 
set of genes known to be crucial to the regulation of each cell type. We thus 
focused our later analyses of this transcriptomic data on more targeted 
approaches rather than broad GO term analyses. 
Among the sets of differentially expressed genes, we identified a set of 
lineage-enriched transcription factors. Of note, most of these factors have not 
been previously linked to somatotrope or lactotrope identity and function (Fig. 
3D). Six differentially expressed transcription factors were chosen for detailed 
study. This selection was based on reports of these six factors having 
mechanisms of action or functions that would be consistent with their suspected 
roles in the somatotrope and lactotrope lineages. In an initial screen, 
immunofluorescence analysis confirmed that four of these six factors were 
robustly enriched in the nuclei of the cell type predicted by their differential 
mRNA expression (Fig. 4). The remaining two factors were not similarly enriched 
and were therefore eliminated from further study. The functional impacts of the 
four validated transcription factors are explored in Chapter III. Together, these 
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transcriptomic analyses not only identify candidate regulators of both the 
somatotrope and lactotrope lineages, but provide a robust data set for further 
probing the transcriptomic differences between these two cell lineages.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures and legends 
 
 
Figure 2. Fluorescence activated cell sorting (FACS) of primary somatotropes and lactotropes from the mouse 
pituitary.  A. Schematic of the two transgenes used for selective isolation of somatotropes and lactotropes. B. 
Representative FACS of pituitary cells harvested from cosGH-eGFP/rPrl-DsRedcyto compound transgenic mice. The X 
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axis represents GFP expression and the Y axis represents DsRed expression. Gating used for sorting is represented by 
rectangles encompassing the sorted populations. C. Relative expression levels of mRNAs encoding the full array of 
anterior pituitary hormones in the whole pituitary, and from the two FACS populations. Normalized reads (FPKM) are 
shown for the anterior pituitary hormone genes in total pituitary (left), FACS sorted GFP+ cells (middle), and FACS sorted 
DsRed+ cells (right). All samples used for transcriptomic analyses were generated from 6-8-week old virgin female mice. 
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Figure 3. RNA-seq analyses of flow sorted GFP+ and DsRed+ cell populations reveal subsets of lineage-enriched 
transcription factors. A. Enrichment (Log2 fold change) of mRNAs in the GFP+ and DsRed+ populations encoding 
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defined markers for somatotropes (green), lactotropes (red), and for markers shared between somatotropes and 
lactotropes (blue). The designation of each respective marker gene is noted at the bottom of the figure. A positive value 
on the Y-axis indicates enrichment in the GFP+ population while a negative value indicates enrichment in the DsRed+ 
population. Significance values relate to the enrichment in mRNA expression between the two flow sorted populations. * 
Indicates p-value of less than 0.05, ** indicates p-value of less than 0.01, n.s. indicates not significant. B. Correlation plot 
of the RNA-seq analysis GFP+ cells vs. DsRed+ cells. The Log2 FPKM values for all mRNAs in the GFP+ (x-axis) and 
DsRed+ (y-axis) samples were plotted, and mRNAs surpassing a threshold of 4-fold enrichment or greater were 
highlighted in red. These enriched mRNAs were then further filtered to remove low expressers, leaving only genes that 
were robustly expressed and significantly enriched (p < 0.05). The positions of Gh and Prl are noted on this plot. C. 
Representative Sashimi plot track showing raw mapped mRNA reads at the Pou1f1 locus in GFP+ and DsRed+ cell 
populations. The identity of the two Sashimi plots indicates identical splicing patterns of the Pou1f1 transcript in 
somatotropes and lactotropes, in accordance with analysis performed using TopHat2 (see Methods). D. List of 
transcription factors enriched in GFP+ vs. DsRed+ cell populations were identified by taking the GFP/DsRed specific 
genes identified by differential expression analysis and using PANTHER to identify genes with known GO terms for 
transcription factor activity.  
3
1
 
 
 
 
Figure 4. Immunofluorescence microscopy validated cell-type specificity of expression for a subset of lineage 
enriched transcription factors. Cells disaggregated from wild type pituitaries (female) were stained for each of six 
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transcription factors whose mRNAs were enriched in the GFP+ cell population (A-C) and the DsRed+ cell population (D-F) 
(as in Fig. 3D). Each transcription factor is stained in green, and cells were co-stained red with antibodies to identify GH 
or PRL as a means of identifying somatotropes and lactotropes, respectively. A. NUPR1, B. RXRG, C. PPARG. D. 
NR4A2. E. POU4F1. F. TBX19. All cells were stained with DAPI (blue) to mark nuclei. Scale bars = 5 μm.  
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Tables 
 
Table 1. Cell counts for immunofluorescence assays. Cell counts for 
immunofluorescence microscopy analyses of selected transcription factors. 
Columns list the number of GH+ or PRL+ cells examined (200 GH+ and 200 PRL+ 
cells counted per study) expressing the given transcription factor, as well as the 
percentage of total somatotropes/lactotropes observed expressing the protein in 
parentheses.  
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Supplemental Data 
 
Supplemental Figure 1. Schematic of GH-GFP transgene and modified version 
of transgene without the growth hormone signal peptide. The previously 
described GH-GFP transgene (top) produces somatotrope-specific GFP 
expression, but the presence of the growth hormone signal peptide (first 24 
amino acids of the GH protein) causes GFP to be secreted as growth hormone 
is, leading to some somatotropes having relatively low GFP levels. By truncating 
the beginning of exon 2 (bottom panel), the signal peptide was reduced from its 
full 24 amino acids to only 8 amino acids, ablating its function and causing the 
GFP protein produced from this transgene to accumulate in the cytoplasm of 
somatotropes. No other modifications were made to the transgene. 
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Supplemental Figure 2. Immunofluorescence microscopy of GH-eGFP pituitary 
cells demonstrating that GFP is selectively expressed in somatotropes. 
Pituitaries from GH-eGFP mice were disaggregated and co-stained for DAPI, 
GFP, GH, and PRL, as indicated in each frame. The red arrows indicate three 
GFP+ cells which are also GH+. The white arrow indicates a PRL+ cell which is 
negative for GFP and GH. The merge frame combines DAPI along with GFP 
(green), GH (red), and PRL (white). A total of 200 somatotropes and 200 
lactotropes (identified by the expression of GH or PRL, respectively) were 
assayed for GFP expression. Out of 200 somatotropes, 184 (92%) were GFP 
positive. Out of 200 lactotropes, 2 (1%) were GFP positive. These data 
demonstrate robust somatotrope specificity for the GH-eGFP line. Scale bar, 5 
um. 
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Supplemental Table 1. Total read counts for GFP and DsRed mRNAs in each 
FACS-sorted sample used for RNA-seq analysis. 
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GO molecular function complete Raw P-
value 
FDR 
carbohydrate:cation symporter activity (GO:0005402) 3.18E-04 4.66E-
02 
lipopolysaccharide binding (GO:0001530) 5.92E-05 1.04E-
02 
carbohydrate transmembrane transporter activity (GO:0015144) 1.87E-04 2.93E-
02 
nuclear receptor activity (GO:0004879) 4.14E-05 7.85E-
03 
transcription factor activity, direct ligand regulated sequence-specific DNA 
binding (GO:0098531) 
4.14E-05 7.54E-
03 
voltage-gated potassium channel activity (GO:0005249) 3.44E-07 5.21E-
04 
steroid hormone receptor activity (GO:0003707) 6.92E-05 1.16E-
02 
potassium channel activity (GO:0005267) 4.03E-07 3.06E-
04 
voltage-gated cation channel activity (GO:0022843) 9.57E-07 3.96E-
04 
potassium ion transmembrane transporter activity (GO:0015079) 3.69E-07 3.36E-
04 
voltage-gated channel activity (GO:0022832) 9.35E-06 2.50E-
03 
voltage-gated ion channel activity (GO:0005244) 9.35E-06 2.36E-
03 
heparin binding (GO:0008201) 1.22E-04 1.98E-
02 
glycosaminoglycan binding (GO:0005539) 1.35E-05 2.93E-
03 
monovalent inorganic cation transmembrane transporter activity 
(GO:0015077) 
3.49E-07 3.97E-
04 
ion gated channel activity (GO:0022839) 3.19E-06 9.67E-
04 
gated channel activity (GO:0022836) 4.25E-06 1.21E-
03 
secondary active transmembrane transporter activity (GO:0015291) 2.26E-04 3.43E-
02 
cation channel activity (GO:0005261) 1.57E-05 3.24E-
03 
ion channel activity (GO:0005216) 1.82E-06 6.88E-
04 
passive transmembrane transporter activity (GO:0022803) 8.62E-07 4.90E-
04 
channel activity (GO:0015267) 8.62E-07 4.36E-
04 
substrate-specific channel activity (GO:0022838) 2.53E-06 8.85E-
04 
metal ion transmembrane transporter activity (GO:0046873) 1.23E-05 2.79E-
03 
cation transmembrane transporter activity (GO:0008324) 4.53E-07 2.94E-
04 
inorganic cation transmembrane transporter activity (GO:0022890) 2.93E-06 9.51E-
04 
ion transmembrane transporter activity (GO:0015075) 4.41E-08 2.01E-
04 
inorganic molecular entity transmembrane transporter activity (GO:0015318) 2.64E-07 6.01E-
04 
lipid binding (GO:0008289) 2.46E-05 4.87E-
03 
transmembrane transporter activity (GO:0022857) 8.99E-07 4.09E-
04 
transporter activity (GO:0005215) 9.46E-06 2.27E-
03 
Supplemental Table 2. Molecular function (GO ontology) terms enriched in 
somatotrope genes. 
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GO molecular function complete Raw P-value FDR 
G-protein coupled nucleotide receptor activity (GO:0001608) 7.82E-06 1.78E-03 
G-protein coupled purinergic nucleotide receptor activity 
(GO:0045028) 
7.82E-06 1.69E-03 
G-protein coupled photoreceptor activity (GO:0008020) 5.48E-04 4.98E-02 
chemokine receptor activity (GO:0004950) 3.64E-07 2.36E-04 
G-protein coupled chemoattractant receptor activity 
(GO:0001637) 
3.64E-07 2.07E-04 
C-C chemokine binding (GO:0019957) 3.64E-07 1.84E-04 
purinergic nucleotide receptor activity (GO:0001614) 8.71E-06 1.80E-03 
nucleotide receptor activity (GO:0016502) 8.71E-06 1.72E-03 
C-C chemokine receptor activity (GO:0016493) 2.64E-06 9.24E-04 
chemokine activity (GO:0008009) 4.64E-10 7.03E-07 
purinergic receptor activity (GO:0035586) 3.40E-06 1.10E-03 
chemokine binding (GO:0019956) 2.03E-06 7.68E-04 
transmitter-gated ion channel activity involved in regulation of 
postsynaptic membrane potential (GO:1904315) 
2.30E-05 3.48E-03 
chemokine receptor binding (GO:0042379) 6.74E-09 6.13E-06 
neurotransmitter receptor activity involved in regulation of 
postsynaptic membrane potential (GO:0099529) 
2.75E-05 3.79E-03 
postsynaptic neurotransmitter receptor activity (GO:0098960) 3.89E-05 4.78E-03 
transmitter-gated channel activity (GO:0022835) 1.05E-05 1.90E-03 
transmitter-gated ion channel activity (GO:0022824) 1.05E-05 1.83E-03 
CCR chemokine receptor binding (GO:0048020) 1.14E-04 1.26E-02 
G-protein coupled peptide receptor activity (GO:0008528) 2.40E-10 1.09E-06 
peptide receptor activity (GO:0001653) 3.96E-10 9.00E-07 
extracellular ligand-gated ion channel activity (GO:0005230) 1.12E-04 1.27E-02 
neurotransmitter receptor activity (GO:0030594) 1.43E-05 2.32E-03 
ligand-gated channel activity (GO:0022834) 6.24E-06 1.77E-03 
ligand-gated ion channel activity (GO:0015276) 6.24E-06 1.67E-03 
ligand-gated cation channel activity (GO:0099094) 3.17E-04 3.07E-02 
hormone binding (GO:0042562) 2.36E-04 2.39E-02 
cytokine activity (GO:0005125) 4.39E-07 2.00E-04 
carbohydrate binding (GO:0030246) 5.92E-07 2.45E-04 
G-protein coupled receptor binding (GO:0001664) 2.84E-05 3.80E-03 
cytokine receptor binding (GO:0005126) 9.83E-06 1.86E-03 
ion gated channel activity (GO:0022839) 3.63E-05 4.59E-03 
gated channel activity (GO:0022836) 5.57E-05 6.49E-03 
G-protein coupled receptor activity (GO:0004930) 8.10E-10 9.21E-07 
ion channel activity (GO:0005216) 1.27E-05 2.15E-03 
passive transmembrane transporter activity (GO:0022803) 7.63E-06 1.93E-03 
channel activity (GO:0015267) 7.63E-06 1.83E-03 
substrate-specific channel activity (GO:0022838) 1.87E-05 2.94E-03 
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cation channel activity (GO:0005261) 5.55E-04 4.95E-02 
receptor ligand activity (GO:0048018) 4.14E-05 4.95E-03 
receptor regulator activity (GO:0030545) 2.47E-05 3.51E-03 
signaling receptor activity (GO:0038023) 2.42E-05 3.54E-03 
molecular transducer activity (GO:0060089) 3.19E-05 4.15E-03 
transmembrane signaling receptor activity (GO:0004888) 1.27E-04 1.37E-02 
protein binding (GO:0005515) 4.59E-04 4.26E-02 
binding (GO:0005488) 4.80E-06 1.46E-03 
molecular_function (GO:0003674) 2.12E-04 2.19E-02 
Unclassified (UNCLASSIFIED) 2.12E-04 2.25E-02 
RNA binding (GO:0003723) 2.61E-04 2.58E-02 
olfactory receptor activity (GO:0004984) 1.02E-07 7.70E-05 
odorant binding (GO:0005549) 3.27E-04 3.10E-02 
 
Supplemental Table 3. Molecular function (GO ontology) terms enriched in 
lactotrope genes 
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CHAPTER III: A SET OF CELL TYPE-ENRICHED 
TRANSCRIPTION FACTORS IMPACTS EXPRESSION OF 
LANDMARK PITUITARY GENES 
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Introduction 
 Transcription factors may act through a variety of mechanisms and can 
exert either activating or repressing effects. Transcription factors enriched in 
either the somatotrope or lactotrope cell populations may have roles in 
enhancing the expression of landmark genes within their cell lineage or they may 
play a role in repressing genes of the reciprocal lineage. For example, a 
transcription factor enriched in somatotropes may have a role in enhancing Gh 
expression or in repressing Prl expression. Elucidating these functional impacts 
as well as their mechanistic bases is crucial to understanding the role that an 
identified transcription factor has in regulating the somatotrope or lactotrope 
lineages.  
 Having identified and validated a set of four candidate transcriptions—two 
expressed in somatotropes and two expressed in lactotropes—we next wanted to 
assess their roles in regulating their respective cell types. Here, we utilize a set of 
murine pituitary-derived cell line models to assay the functional impacts of each 
of the candidate transcription factors on known landmark genes in both the 
somatotrope and lactotrope lineages. These transcription factors were also 
assessed for occupancy at chromatin sites encompassing the Gh and Prl gene 
promoters. Mechanistic studies reveal that one of the lactotrope-enriched factors 
binds adjacent to POU1F1 at the Prl gene promoter and synergizes with 
POU1F1 in stimulation of Prl gene transcription by enhancing the release of Pol II 
from the Prl promoter. In contrast, a second factor was found to repress Prl 
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expression in somatotropes through an indirect mechanism. These studies 
highlight and begin to define the variety of mechanisms that underlie lineage 
specificity in the mammalian pituitary. 
Results 
Functional assessment of candidate transcription factors: impacts on 
somatotrope and lactotrope gene expression in cell culture  
 To determine the functional impact of the four candidate factors on 
somatotrope and lactotrope identity, we expressed each factor in a murine 
pituitary-derived cell line, Pit-1/Triple28. Pit-1/Triple cells, isolated by T-antigen 
immortalization of mouse pituitary cells, express POU1F1 (also referred to as 
PIT-16) as well as the three POU1F1 dependent hormones: GH, PRL, and TSH. 
The Pit-1/Triple cells express robust levels of Pou1f1 and express each of the 
Gh, Prl, and Tshb mRNAs at levels substantially lower than those detected in 
whole adult mouse pituitary28. On the basis of this profile of gene expression, we 
have proposed that these Pit-1/Triple cells may represent cells at an early stage 
in pituitary development, immediately following the activation of Pou1f1 but prior 
to terminal differentiation of the individual hormone expressing lineages28 
(corresponding to the “Triple positive, e14.5” cells noted in Fig. 1). 
Transcriptomic analyses of the Pit-1/Triple cells (unpublished data) revealed that 
each of the four candidate transcription factors identified and validated in 
Chapter II is either not expressed or expressed at low levels. We hypothesized 
that forced expression of each of the factors would have a specific impact on 
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genes that in some manner define lactotrope or somatotrope cell identity. To test 
this hypothesis, each candidate factor was ectopically expressed in Pit-1/Triple 
cells from a bi-cistronic expression vector containing the transcription factor ORF 
and a GFP ORF behind an internal ribosome entry site (IRES) (see details in 
Methods). 48 hours post transfection, GFP+ Pit-1/Triple cells were isolated by 
FACS. RNA was isolated and assayed by qRT-PCR to assess impacts of each 
factor on the expression of somatotrope and lactotrope marker genes. The 
expression of each target gene was compared to the corresponding mRNA levels 
in GFP+ cells isolated from a control transfection with an empty (GFP-only) 
vector.  
A panel of five lineage marker genes was assayed in each qRT-PCR 
assay. Gh and the growth hormone releasing hormone receptor (Ghrhr) were 
assayed as markers of the somatotrope lineage while Prl and the dopamine 
receptor (Drd2) were assayed as markers of the lactotrope lineage. Pou1f1 was 
included in the panel of assayed genes as a gene that is common to both 
lineages. This panel of genes, while not encompassing a comprehensive set of 
somatotrope/lactotrope markers, includes the most prominent known markers 
and thus serves as a useful metric for assaying changes in the expression of 
genes crucial to these two lineages.  
Ectopic expression of the somatotrope candidate factor, Nupr1, in the Pit-
1/Triple cells caused a significant repression of both Prl and Drd2 while failing to 
impact on expression of Gh or Ghrhr (Fig. 5A). This impact of Nupr1 would be 
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consistent with a role for this somatotrope-enriched factor in selectively 
repressing the expression of lactotrope genes in the somatotrope lineage. 
Expression of Rxrg failed to impact the expression of any of the assayed genes 
(Fig. 5B), even in the presence of its ligand, retinoic acid (Supplemental Figure 
3)73,74, and so Rxrg was excluded from further study. Expression of the lactotrope 
candidate factors, Nr4a2 and Pou4f1, both resulted in a significant increase in Prl 
expression and while leaving the expression of the other assayed genes 
unchanged (Fig. 5C, D). These data are consistent with these two lactotrope-
enriched factors serving to enhance the expression of Prl in the lactotrope 
lineage. In sum, the data from these cell transfection studies support potential 
reciprocal roles for three lineage-enriched factors; activating lactotrope specific 
genes linked to lactotrope identity (Nr4a2 and Pou4f1), and repressing lactotrope 
specific genes to maintain somatotrope identity (Nupr1).  
Characterization of transcriptional regulatory mechanisms at the Prl 
promoter of the lineage-enriched transcription factors  
The mechanism of action by which a regulatory factor affects the 
transcription of a gene can be direct or indirect. One indication of direct action on 
transcription is the occupancy of the factor at regulatory elements linked to the 
gene of interest. Nr4a2 and Pou4f1 both enhance Prl expression when 
expressed in Pit-1/Triple cells (Fig. 5C, D), raising the possibility of direct binding 
at the Prl promoter. Two binding sites for both NR4A2 and POU4F1 are predicted 
within a 250 bp region of the Prl promoter by JASPAR analysis75, and these sites 
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are intermingled with 4 known POU1F1 binding sites21,75. Of particular interest 
was the observation that one of the NR4A2 predicted binding sites is located 
immediately adjacent to the POU1F1 binding site most proximal to the Prl start 
codon (Fig. 6A). This close positioning of the POU1F1 and NR4A2 binding sites 
raises the possibility that NR4A2 and POU1F1 interact at the Prl promoter. Pit-
1/Triple cells expressing recombinant NR4A2 or POU4F1 were generated and 
enriched by FACS (as above), and chromatin was assayed for factor occupancy 
at the Prl promoter. The MyoD promoter was assayed as a control for non-
specific binding and the Gh promoter was assayed as a specificity control. 
Additional sites 500 bp upstream and downstream of the Prl promoter were also 
assayed to confirm that any binding at the promoter was promoter-specific. The 
NR4A2 ChIP revealed significant and specific binding at the Prl promoter (Fig. 
6B), while a parallel ChIP assay for POU4F1 failed to reveal evidence of 
significant binding in this region. POU4F1 binding to its known autoregulatory 
element76 confirmed the efficacy of the POU4F1 ChIP study. (Fig. 6C, D). In 
order to confirm that NR4A2 binds to the Prl promoter in vivo, NR4A2 ChIP was 
performed on chromatin isolated from FACS-sorted mouse lactotropes (Fig. 6E). 
The data from the analysis of these primary mouse cells demonstrated selective 
in vivo binding of NR4A2 at the Prl promoter. Thus, these ChIP studies along 
with the preceding gene expression assays reveal that NR4A2 is recruited to the 
Prl promoter and enhances Prl gene expression. In contrast, POU4F1 does not 
bind the Prl promoter and thus the enhancement of Prl expression observed in 
the Pit-1/Triple cell transfection study may reflect its binding to an as yet 
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uncharacterized regulatory element beyond the proximal Prl promoter, or through 
an indirect mechanism.  
The lactotrope-enriched transcription factor, NR4A2, acts in conjunction 
with POU1F1 to enhance Prl gene expression. 
The binding of NR4A2 adjacent to a POU1F1 binding site within the Prl 
promoter suggested a model in which NR4A2 works in concert with POU1F1 to 
support Prl gene expression. This model was tested by transfections of the two 
factors either alone or in combination into the Pit-1/0 cell line28. Pit-1/0 cells, 
generated by SV40 T-antigen mediated transformation of mouse pituitary cells 
(as with the Pit-1/Triple cells), model an early stage of anterior pituitary 
development in which Pou1f1 is activated, but not yet expressed at significant 
levels, and in which none of the three POU1F1-dependent hormone genes (Gh, 
Prl, and Tshb) have yet been activated (corresponding to the “Pou1f1+ cell, 
e13.5”; Fig. 1)28. Pit-1/0 cells were transfected with plasmids encoding either 
Pou1f1 or Nr4a2 alone, or with a 1:1 mix of the two expression vectors. Cells 
transfected with the Pou1f1 expression vector alone exhibited a 4-fold increase in 
Prl expression over a vector control (Fig. 6F). Although a parallel transfection 
with Nr4a2 plasmid alone displayed no activation of Prl expression, co-
transfection of Nr4a2 plasmid with the Pou1f1 plasmid stimulated Prl expression 
8-fold over the vector control. There was no apparent impact of the factor 
transfections, either alone or in combination, on the other marker genes in the 
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assay panel. These data suggest that NR4A2 requires the presence of POU1F1 
to enhance expression of the Prl gene.  
NR4A2 fails to enhance POU1F1 occupancy at the Prl promoter or 
enhance the presence of activating chromatin marks 
What is the mechanism by which NR4A2 enhances POU1F1 actions at 
the Prl promoter? One potential mechanism is by facilitating recruitment of 
POU1F1 to the Prl promoter. To test this hypothesis, POU1F1 occupancy was 
assayed by ChIP in Pit-1/Triple cells expressing exogenous NR4A2 and 
compared to POU1F1 occupancy in Pit-1/Triple cells not expressing NR4A2 (Fig. 
7). The ChIP was performed using a POU1F1 antibody generated in the lab and 
validated by demonstrating specific detection of POU1F1 (Supplemental Figure 
4). This experiment revealed no enhancement of POU1F1 occupancy at the Prl 
promoter in the presence of NR4A2. Thus, the functional interaction of NR4A2 
with POU1F1 at the Prl promoter does not rely on increasing POU1F1 
recruitment to the Prl promoter.  
Having observed that NR4A2 binds the Prl promoter adjacent to a known 
POU1F1 binding site and that NR4A2 does not enhance the binding of POU1F1, 
we next hypothesized that NR4A2 may play a role in histone modification at the 
Prl promoter prior to transcription. Histone acetylation constitutes an early step 
towards initiating transcription77,78, and histone 3 lysine 27 (H3K27) acetylation 
as well as histone 3 lysine 4 (H3K4) tri-methylation have been identified as 
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promoter marks that strongly correlate with active transcription79-81. To test our 
hypothesis, we assayed changes in H3K27 acetylation and H3K4 tri-methylation 
at both the Gh and Prl promoters in Pit-1/0 cells transfected with Pou1f1 or Nr4a2 
alone, or transfected with a 1:1 mix of both factors. Pit-1/0 cells were used in this 
assay because the Gh, Prl, and Pou1f1 genes are inactive, making these cells a 
useful model for detecting epigenetic modifications at these loci that track with 
the process of transcriptional activation. Transfection with Pou1f1 alone caused a 
significant increase in H3K27 acetylation at both the Gh and Prl promoters, 
consistent with the known roles of POU1F1 in activating both of these genes 
(Fig. 8A). In contrast, transfection with Nr4a2 alone did not cause an increase in 
H3K27 acetylation over an empty vector control, and cells transfected with both 
Pou1f1 and Nr4a2 had levels of H3K27 acetylation similar to those of cells 
transfected with Pou1f1 alone. A similar effect was observed when assaying 
changes in H3K4me3 levels (Fig. 8B) with expression of Pou1f1 alone causing 
an increase in H3K4me3 levels at both the Gh and Prl promoters while the 
addition of Nr4a2 caused no significant change in H3K4 tri-methylation over the 
level observed in the presence of Pou1f1 alone. These data indicate that 
POU1F1 is sufficient to recruit histone acetylases and methylases to impart 
activating modifications at both the Gh and Prl promoters. The data further 
suggest that these activating modifications imparted by POU1F1 are not 
sufficient for selective transcriptional activation of Gh vs. Prl, as Pou1f1 
selectively increases levels of Prl but not Gh mRNA in the Pou1f1 transfected Pit-
1/0 cells (Fig. 6F). Finally, the data indicate that NR4A2 appears to enhance Prl 
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expression via a mechanism unrelated to any augmentation in H3K27 acetylation 
or H3K4 tri-methylation over that imparted by POU1F1. Taken together, these 
data lead us to conclude that the lactotrope-enriched factor, NR4A2, binds 
adjacent to POU1F1 at the Prl promoter and synergizes with POU1F1 to 
enhance Prl gene expression through a mechanism that is unrelated to POU1F1 
recruitment or to the augmentation of defined histone modifications. 
NR4A2 binding at the Prl promoter is POU1F1 dependent 
In our preceding studies we determined that NR4A2 and POU1F1 bind at 
adjacent sites in the Prl gene promoter, that NR4A2 does not impact on POU1F1 
occupancy at the Prl promoter, nor does it augment the levels of activating 
modifications at the Prl promoter. We also demonstrated that Nr4a2 has no 
impact on Prl gene expression in the absence of Pou1f1. These data could be 
unified in a model in which POU1F1 initially binds to the Prl promoter and makes 
the adjacent chromatin of the promoter accessible for NR4A2 binding. To 
determine if NR4A2 binding at the Prl promoter is in fact POU1F1 dependent, we 
transfected Pit-1/0 cells (which express neither Nr4a2 nor appreciable levels of 
Pou1f1) with combinations of plasmids expressing Nr4a2 and Pou1f1. These 
cells were harvested, chromatin isolated and the occupancy of NR4A2 at the Prl 
promoter was assessed by NR4A2 ChIP. NR4A2 protein binding to the Prl 
promoter was only observed in cells that co-expressed Nr4a2 and Pou1f1. There 
was no evidence of binding of NR4A2 in cells containing Nr4a2 but lacking 
Pou1f1 (Fig. 9). Thus POU1F1 plays an essential role in facilitating the binding of 
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NR4A2 at the Prl promoter. These data, in conjunction with the prior observation 
that Nr4a2 can only enhance Prl expression in the presence of Pou1f1 (Fig. 6F), 
suggest a model in which NR4A2 binds at the Prl promoter in a POU1F1-
dependent manner and enhances Prl expression in conjunction with, and fully 
dependent on the co-binding of POU1F1. This conclusion raises the mechanistic 
question of how NR4A2 acts to enhance the action of POU1F1 at the Prl 
promoter. 
NR4A2 enhances the release of RNA polymerase II from the Prl promoter, 
increasing transcription 
The observation that NR4A2 binding was selective to the Prl promoter vs. 
the Gh promoter and that its functions were dependent on Pou1f1 raised the 
possibility that it served to in some way potentiate Pou1f1 actions on Prl. Based 
on the preceding data we hypothesized that NR4A2 may enhance Prl 
transcriptional activity by augmenting in some manner the recruitment of RNA 
polymerase II (Pol II) to the Prl promoter or by enhancing the actions of Pol II 
once recruited. To initially test these models, we transfected Pit-1/0 cells with 
plasmids that express Pou1f1 and Nr4a2 (see above and Methods) and assayed 
Pol II occupancy at key regulatory elements of the Prl locus as well as regulatory 
elements at the Gh and Pou1f1 loci (Fig. 10). This Pol II ChIP study produced 
the noteworthy observation that Pol II recruitment to the Prl promoter is 
dependent on the actions of Pou1f1 and that this recruitment to the Prl promoter 
is not impacted to any extent by the co-expression of Nr4a2. Surprisingly, 
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however, the ChIP analysis revealed that Nr4a2 robustly enhanced the presence 
of Pol II within the Prl gene body (Fig. 10, “Prl downstream”). Together, these 
data suggest that NR4A2 has an impact on Prl promoter function that is distal to 
POU1F1 binding and distal to Pol II recruitment. One possible mechanistic model 
that fits these findings is that NR4A2 plays a role in the release of Pol II from the 
Prl promoter into the gene body. 
The observation that NR4A2 may be involved in the release of Pol II from 
the Prl promoter prompted us to hypothesize that NR4A2 plays a role in 
recruiting Pol II release factors to the Prl promoter. The major release factor that 
permits the release of Pol II from promoters is P-TEFb, composed of Cdk9 and 
cyclin T182,83. To determine if NR4A2 enhances recruitment of P-TEFb to the Prl 
promoter, we transfected Pit-1/0 cells with plasmids expressing Pou1f1 and 
Nr4a2 and performed ChIP for the Cdk9 component of P-TEFb. The presence of 
POU1F1 stimulated significant increases in Cdk9 occupancy at both the Gh and 
Prl promoters, as well as a robust recruitment of Cdk9 to the auto-regulatory 
Pou1f1 promoter9 (Fig. 11). Remarkably, however, there was no significant 
increase in Cdk9 occupancy at the Prl promoter in cells co-expressing POU1F1 
and NR4A2 as compared with POU1F1 alone. We conclude from these studies 
that the selective stimulatory impact of NR4A2 on Pol II release from the Prl 
promoter appears to act by a P-TEFb independent pathway. These data 
establish a foundation for future studies that focus on identifying the components 
and mechanism of Nr4a2-mediated Pol II release at the Prl promoter. 
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Discussion 
We have previously identified a set of transcription factors enriched in 
either somatotropes or lactotropes (Chapter II). The four transcription factors 
with appropriate localization and enrichment by immunofluorescence analysis 
were subsequently assessed for functions relevant to lineage identity by 
expression of the recombinant proteins in the Pit-1/Triple cell line. Our studies of 
the somatotrope-enriched transcription factor, Nupr1, were highly informative. 
Ectopic expression of Nupr1 in the Pit-1/Triple cells, caused a decrease in the 
two most prominent lactotrope gene markers, Prl and Drd2. This action suggests 
that the somatotrope factor Nupr1 exerts a repressive action on lactotrope 
specific genes, an activity that could contribute to the maintenance of 
somatotrope lineage identity (Fig. 5A). It is of note that Nupr1-/- mice have been 
reported to be fertile and of normal size54. The normal size of these Nupr1-/- mice 
is consistent with our observations that Nupr1 expression does not impact Gh 
levels. Based on the repressive effect of Nupr1 on Prl expression in the Pit-
1/Triple cells, we would predict that Nupr1-/- mice will display elevated levels of 
Prl expression. The observation that Nupr1-/- mice are fertile suggests that the 
loss of Prl repression in somatotropes is not to an extent sufficient to result in 
fertility problems. Such conclusions can be best addressed by in vivo condition 
gene modification studies, as described in Chapter IV. Of further interest is our 
observation that NUPR1 is expressed in approximately half (54%) of 
somatolactotropes (Supplemental figure 5). These data suggest that NUPR1 is 
not fully sufficient to repress Prl expression and that there are likely other factors 
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involved in repressing Prl expression in the somatotrope lineage, either additively 
or synergistically with NUPR1. Transcription factor binding site analyses did not 
identify a putative binding site for NUPR1 within the Prl promoter, suggesting that 
the mechanism of action may be indirect or may be dependent upon NUPR1 
binding at a currently unknown Prl regulatory element. While the current study 
did not identify a reciprocally-acting transcription factor in lactotropes that 
represses somatotrope genes in lactotropes, it would be reasonable to 
hypothesize that such factors exist and future studies will aim to identify them.  
Expression of the second somatotrope-enriched factor, Rxrg, in Pit-
1/Triple cells did not significantly alter the expression of the assayed genes (Fig. 
5B) even after the addition of retinoic acid, a known ligand of RXRG, to the tissue 
culture medium during transfection (Supplemental Figure 3)73. While this result 
does not preclude a function for Rxrg in regulating the expression of somatotrope 
genes that were not represented in our experimental approach, Rxrg was 
excluded from further study in order to focus on transcription factors that impact 
the expression of the landmark somatotrope and lactotrope genes.  
Both of the lactotrope-enriched factors, Pou4f1 or Nr4a2, were notable for 
a significant enhancement in Prl expression when expressed in Pit-1/Triple cells 
(Fig. 5C, D). The lack of a significant change in Drd2 expression when these 
factors were ectopically expressed suggested that they target expression of the 
Prl gene, rather than impacting on multiple genes in the lactotrope transcriptional 
program. Taken together, our transcription factor data reveal transcription factor 
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actions that either enhance expression of a lineage-defining gene or repress 
expression of genes from a competing lineage. These observations further 
support a model in which these cells must actively repress the transcriptional 
program of the reciprocal lineage to maintain their cell identities and functions.  
The function of the transcription factor NR4A2 was further explored by a 
combination of ChIP studies and cell transfection assays. NR4A2 ChIP analysis 
revealed direct binding to the Prl promoter in Pit-1/Triple cells (Fig. 6B). A 
parallel ChIP assay conducted using a primary cell pool enriched for lactotropes 
(Fig. 6E) confirmed that this same binding to the Prl promoter occurs in vivo. This 
suggests a mechanistic basis for NR4A2 activation of Prl gene expression via a 
direct interaction with the Prl promoter, and the concordance of the NR4A2 ChIP 
assays in both primary lactotropes and the Pit-1/Triple cell line supports the 
validity of using the Pit-1/Triple cell line as an experimental model. qRT-PCR 
assays performed on Pit-1/0 cells expressing Pou1f1, Nr4a2, or both factors 
together provided further insight into the mechanism of action for Nr4a2 (Fig. 
6F). Expression of Pou1f1 alone activated Prl while the expression of Nr4a2 
alone had no effect. However, co-expression of Nr4a2 with Pou1f1 resulted in a 
significant enhancement of Prl expression over that seen with Pou1f1 alone. 
These data suggest that NR4A2 is not sufficient to activate Prl expression on its 
own, but that it acts synergistically when POU1F1 is present at the Prl promoter 
to enhance Prl expression. 
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The positioning of an NR4A2 binding site in the Prl promoter adjacent to a 
functionally-defined POU1F1 binding site suggested that its function(s) may 
involve enhancement of POU1F1 and occupancy. However, a POU1F1 ChIP 
analysis failed to reveal a significant impact of NR4A2 on POU1F1 occupancy at 
the Prl promoter (Fig. 7). Additionally, a ChIP analysis of the Gh and Prl 
promoters in Pit-1/0 cells transfected with Pou1f1, Nr4a2, or both factors 
revealed that POU1F1 establishes H3K27 acetylation and H3K4 tri-methylation 
while NR4A2 has no apparent effect on its own, nor does it enhance the 
modifications seen with Pou1f1 alone (Fig. 8). Based on these observations we 
conclude that NR4A2 enhancement of Prl expression relates to a synergistic 
interaction between the two bound factors at the Prl promoter rather than 
reflecting enhancements of POU1F1 occupancy or a role in promoting histone 
H3K27 acetylation or H3K4 tri-methylation at the target promoter. Reports from 
other systems indicate that the family of nuclear orphan receptors to which Nr4a2 
belongs is able to heterodimerize with a wide range of transcription factors and 
drive transcription84-86, suggesting that NR4A2 might heterodimerize with 
POU1F1 or with other, currently unknown, transcription factors at the Prl 
promoter to exert its actions on productive transcription. 
We next sought to elucidate the mechanism by which the NR4A2 protein 
exerts this enhancer effect. Knowing that POU1F1 binds the Prl promoter 
independent of NR4A2 occupancy (Fig. 7), we next performed a reciprocal 
experiment, performing NR4A2 ChIP using chromatin isolated from Pit-1/0 cells 
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to determine whether NR4A2 occupancy at the Prl promoter requires POU1F1 
(Fig. 9). These Pit-1/0 cells do not express Pou1f1 or Nr4a2 on their own. After 
transfection with either Nr4a2 alone or Nr4a2 and Pou1f1, this ChIP assay 
revealed that NR4A2 requires POU1F1 in order to bind the Prl promoter. This 
observation is consistent with previous data demonstrating that the enhancement 
of Prl gene expression by Nr4a2 is dependent on Pou1f1 actions (Fig. 6F). 
These data lead us to propose a model in which POU1F1 binds the Prl promoter 
and activates Prl expression, followed by NR4A2 binding at the Prl promoter 
which further enhances Prl expression. 
Next, we hypothesized that the enhancing activity of NR4A2 reflects its 
ability to enhance the recruitment of Pol II to the Prl promoter in the presence of 
POU1F1. To test this hypothesis, we performed ChIP for serine 5 phosphorylated 
RNA polymerase II (Pol II) at the Prl promoter as well as regions 500 bp 
upstream (“Prl upstream”) and 500 bp downstream within the Prl gene body (“Prl 
downstream”) (Fig. 10). The serine 5 phosphorylated form of Pol II is associated 
with initiation of transcription and active transcription87,88. Serine 5 
phosphorylated Pol II occupancy was detected in equal levels at the Prl promoter 
in cells that express Pou1f1 alone and in cells that express both Pou1f1 and 
Nr4a2, suggesting that Pou1f1 expression is sufficient to recruit Pol II and 
assemble a pre-initiation complex (PIC) at the Prl promoter. The Pol II ChIP 
studies revealed that Pol II occupancy downstream in the Prl gene body was 
markedly enhanced by co-expression of Nr4a2 with Pou1f1. Pol II occupancy at 
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the region approximately 500 bp upstream of the Prl promoter is also enhanced 
by expression of Pou1f1 and further enhanced by the co-expression of Pou1f1 
and Nr4a2. This increase in Pol II occupancy at regions both upstream and 
downstream of the Prl promoter may be indicative of bidirectional transcription, 
which is a previously described phenomenon at many active promoters89-91. As 
was expected, given the lack of NR4A2 in somatotropes and the lack of binding 
sites at the Gh promoter, the expression of Nr4a2 in the Pit-1/0 cell line failed to 
impact on Pol II occupancy at the promoter or within the body of the Gh gene 
(see also Supplemental Figure 6). These data suggest that NR4A2 enhances 
the release of Pol II from the Prl promoter and into the Prl gene body for active 
transcription.  
The basis for the NR4A2-enhanced release of Pol II from the Prl promoter 
was further investigated by asking if it reflected an enhanced recruitment of 
known release co-factors. While we observed no evidence that NR4A2 enhances 
recruitment of the prominent Pol II release factor, P-TEFb (Fig. 11), there are 
other mechanisms by which NR4A2 may trigger the release of Pol II such as by 
recruiting a different release factor, ejecting a negative release factor, or by 
stabilizing the Pol II transcriptional machinery at the Prl promoter. These data 
lead us to hypothesize a model in which POU1F1 binds at the Prl promoter and 
activates Prl expression. This POU1F1 occupancy is followed by NR4A2 binding 
in a POU1F1-dependent manner at the Prl promoter and further increasing the 
rate of transcription of Prl by triggering the release of Pol II from the Prl promoter 
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(outlined in Fig. 12). The identity of factor(s) involved in the NR4A2 enhancement 
of Pol II release can now be directly addressed as summarized in Chapter V. 
The observation of a novel, cell-type enriched transcription factor binding 
to the promoter of the Prl gene and acting in conjunction with POU1F1 offers a 
potential explanation to the dilemma of Pou1f1 being expressed in both 
somatotropes and lactotropes, yet selectively driving the production of one 
hormone protein per cell type. While POU1F1 binding at the Gh and Prl 
promoters may be ubiquitous in somatotropes and lactotropes, and prime the 
respective promoters via targeted histone acetylation, the presence or absence 
of additional, lineage-enriched factors such as NR4A2 may be the crucial 
determinant of which hormone gene is activated by POU1F1 in a cell. It is also 
noteworthy that some factors, such as POU4F1, have effects on the expression 
of lineage markers such as Prl, yet are not observed to directly bind the 
promoters of either hormone gene (Fig. 6D). These data suggest that POU4F1 
acts on other, currently unidentified, regulatory elements to alter the expression 
of genes critical to cell identity such as Prl.  
In conclusion, these analyses support a model in which cell type-enriched 
transcription factors are likely induced during the transition from precursor cells 
into a somatotrope or lactotrope. These factors then enhance the expression of 
genes crucial to cell identity or suppress the genes that drive the reciprocal 
lineage. These factors continue to be expressed in adult pituitary cells, and are 
likely needed for the maintenance of cell fate. Mechanistically, these transcription 
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factors can act directly at the promoters of their target genes, or indirectly via 
additional mediators. The newly identified transcription factors presented here 
are likely to represent only a subset of the factors that play important roles in the 
maintenance of somatotrope and lactotrope cell identities. The identification of 
additional lineage defining determinants is now possible through the analysis of 
the transcriptomic profiles of both cell types. 
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Figures and legends 
 
 
Figure 5. Impact of four validated lineage-enriched transcription factors on 
expression of somatotrope and lactotrope marker genes in Pit-1/Triple 
cells. Pit-1/Triple cells28 were transfected with expression constructs encoding 
each noted transcription factor linked by an IRES to a GFP reporter ORF (See 
Methods). Transfected cells were isolated by GFP FACS and their RNA content 
was assayed for specific marker gene expression by qRT-PCR. A. Nupr1. B. 
Rxrg. C. Nr4a2. D. Pou4f1. In all assays, expression of the recombinant 
transcription factor was confirmed by targeted qRT-PCR (data not shown). Gene 
expression was normalized to an internal Gapdh control and the fold change over 
empty vector controls was calculated using the ΔΔCt method (see Methods). 
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Gapdh expression levels were stable across all assayed conditions, with no 
significant changes in Gapdh expression in any of the transfected samples. Error 
bars indicate one standard deviation. Significance calculated by T-test, * 
indicates a p-value of <0.05. n = 5 for all experiments. 
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Figure 6. The lactotrope-enriched transcription factor, NR4A2, acts in 
conjunction with POU1F1 at the Prl promoter to enhance Prl expression. A. 
Schematic of the mPrl gene promoter indicating the relative positions of known 
POU1F1 binding sites (blue ovals,21) as well as predicted binding sites for 
NR4A2 (red ovals) (identified by JASPAR), along with primer positions used for 
amplification in ChIP assays (red arrows). B. NR4A2 ChIP. Pit-1/Triple cells were 
transfected with an expression vector encoding NR4A2 and chromatin isolated 
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from GFP+ cells (as in Fig. 5) was assayed by NR4A2 ChIP. Levels of 
transcription factor occupancy at specific sites within the Prl promoter were 
quantified by qRT-PCR of immunoprecipitated samples. Parallel controls 
included quantitation of occupancy at the Gh promoter and assessment of 
binding in regions 500 bp upstream and downstream of Prl promoter. The MyoD 
promoter served as a negative control in all studies. C. Schematic of the mPrl 
gene promoter indicating the relative positioning of known POU1F1 binding sites 
(blue ovals) as well as predicted binding sites for POU4F1 (green ovals) 
(identified by JASPAR). D. POU4F1 ChIP. Pit-1/Triple cells were transfected with 
an expression vector encoding POU4F1 and chromatin isolated from GFP+ cells 
(as in B.) was assayed by ChIP. The Pou4f1 enhancer, which contains an 
autoregulatory POU4F1 binding site, was assayed in this study as a positive 
control for the POU4F1 ChIP76. E. NR4A2 ChIP on FACS sorted mouse 
lactotropes revealed a similar binding profile as that observed in Pit-1/Triple cells, 
confirming the validity of the cell line model. F. NR4A2 enhances Pou1f1-
dependent activation of the Prl gene in Pit-1/0 cells. Pit-1/0 cells were transfected 
with expression vectors encoding Pou1f1, Nr4a2, or both linked by IRES to GFP, 
and GFP+ cells were collected by FACS. qRT-PCR analysis was performed to 
measure changes in mRNA expression of somatotrope and lactotrope marker 
genes. *: p-value <0.05. **: p-value <0.01. ***: p-value <0.001. n = 3 for all 
experiments. 
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Figure 7. NR4A2 has no significant impact on POU1F1 occupancy at the Prl 
promoter. POU1F1 chromatin immunoprecipitations were carried out on Pit-
1/Triple cells +/- Nr4a2. Pit-1/Triple cells, which do not express Nr4a2 on their 
own, were transfected with an Nr4a2 expression vector (the same Nr4a2-IRES-
GFP plasmid used in assays presented in Fig. 5C), and control cells were 
transfected with the empty IRES-GFP vector. GFP positive cells were sorted by 
FACS, chromatin was isolated, and ChIP was performed using an antibody that 
recognizes POU1F1. Following immunoprecipitation, qRT-PCR was used to 
measure the relative levels of POU1F1 binding in Pit-1/Triple cells that had been 
transfected with Nr4a2 plasmid (+Nr4a2), and those transfected with empty 
vector. Immunoprecipitations using IgG served as a negative control. * indicates 
p-value <0.05. N = 3 biological replicates. 
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Figure 8. Expression of Nr4a2 does not impact levels of histone 3 lysine 27 
acetylation or histone 3 lysine 4 tri-methylation. Pit-1/0 cells, which express 
neither Nr4a2 nor appreciable levels of Pou1f1, were transfected with Nr4a2-
IRES-GFP, Pou1f1-IRES-GFP, or a 1:1 mixture of both expression vectors, and 
control cells were transfected with an empty IRES-GFP vector. Cells transfected 
with the 1:1 mixture of the Pou1f1 and Nr4a2 expression vectors express lower 
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levels of each protein due to the concentration of each expression vector being 
halved during transfection in order to keep the total amount of DNA constant in 
each transfection. GFP positive cells were isolated by FACS and chromatin was 
isolated. ChIP was performed using an antibody that recognizes histone 3 lysine 
27 acetylation (H3K27ac) (A.), or an antibody that recognizes histone 3 lysine 4 
tri-methylation (H3K4me3) (B.). Following chromatin immunoprecipitation, qRT-
PCR was performed to assay the levels of each marker at the Gh promoter, the 
Prl promoter, and the MyoD promoter as a negative control. IgG controls (data 
not shown) were also included in this assay for all samples. In all cases, ChIP 
performed with IgG yielded <1% of input. * indicates a p-value <0.05. N = 3 
biological replicates. 
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Figure 9. NR4A2 binding at the Prl promoter is POU1F1 dependent. Pit-1/0 
cells were transfected with plasmids expressing either Nr4a2 or Pou1f1 linked by 
IRES to a GFP reporter as in Figure 6. GFP positive transfected cells were 
collected and chromatin was isolated before performing ChIP for the NR4A2 
protein. NR4A2 occupancy was assayed at the promoters of Gh, Prl, Pou1f1, and 
Myod as a control. * indicates p-value <0.05 as determined by Student’s T-test. N 
= 3 biological replicates. 
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Figure 10. NR4A2 enhances the release of Pol II from the Prl promoter into 
the gene body. Pit-1/0 cells were transfected with either Pou1f1 alone, or with a 
combination of Pou1f1 and Nr4a2, with untransfected cells serving as a negative 
control. ChIP was performed for serine 5 phosphorylated Poll II and binding was 
quantified by qPCR. The Gh, Pou1f1, and Prl promoters were assayed along with 
upstream and downstream controls for specificity. Here, “upstream” refers to 
regions 500 bp upstream of the canonical promoters and “downstream” refers to 
500 bp downstream of the promoters, inside the gene body. * indicates p-value 
<0.05, ** indicates p-value <0.01 as determined by Student’s T-test. N = 3 
biological replicates. 
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Figure 11. NR4A2 fails to enhance Cdk9 recruitment at the Gh and Prl 
promoters. Pit-1/0 cells were transfected with plasmids expressing Pou1f1 alone 
or co-expressed with expression constructs for both Pou1f1 and Nr4a2 and 
chromatin immunoprecipitation was performed using an antibody against the 
Cdk9 subunit of the release factor P-TEFb. RT-PCR was performed to assay 
Cdk9 occupancy at the Gh and Prl promoters, with the Pou1f1 and Myod 
promoters serving as positive and negative controls, respectively. N = 3 
biological replicates.  
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Figure 12. Model of the role of NR4A2 in enhancing the expression of Prl. 
POU1F1 binds the Prl promoter independently of NR4A2 (1) and triggers histone 
acetylation and tri-methylation throughout the Prl promoter by recruiting histone 
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acetyltransferases and methyltransferases, respectively (2). POU1F1 is able to 
recruit Pol II to the Prl promoter, which activates transcription and leads to some 
measure of Prl expression (3). NR4A2 binds the Prl promoter only in the 
presence of POU1F1, potentially recruiting a release factor to the complex (4), 
and further enhances the rate of Prl transcription by triggering an increase in the 
rate of Pol II release from the Prl promoter (5). 
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Supplemental Data 
 
 
Supplemental Figure 3. RXRG has no impact on the expression of 
signature somatotrope or lactotrope genes in the presence of retinoic acid. 
Pit-1/Triple cells were transfected with an Rxrg expression vector as in Fig. 5 and 
grown in culture medium supplemented with 10 mM retinoic acid (RA). Cells 
transfected with an empty vector control were grown in both with and without RA 
added to the culture medium. Two days after transfection, RNA was collected, 
cDNA generated, and qRT-PCR for each of the indicated mRNAs was performed 
as in Fig. 5. Egr1 was included as a positive control for RA effect based on a 
previous report that it is transcriptionally activated by retinoic acid74 and is 
expressed in Pit-1/Triple cells (data not shown). All data was normalized to the 
Gapdh mRNA signal. Rxrg expression from the Rxrg expression vector was 
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confirmed in transfected cells by PCR (data not shown). N=3, * = p-value <0.05 
as determined by Student’s T-test. 
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Supplemental Figure 4. Western blot validation of POU1F1 antibody 
specificity. POU1F1 antibody was used to perform a western blot on lysate from 
the murine Pit-1/Triple cells (lane 1), producing a band of 33 kDa corresponding 
to endogenous POU1F1. Lysate from human 293T cells (lane 2) produce no 
bands (293T cells do not express POU1F1). 293T cells transfected with a biotin 
ligase receptor peptide (2.5 kDa) epitope-tagged version of POU1F1 (lane 3) 
produces a band with a corresponding shift in size in accordance with the 
additional epitope added to POU1F1 (33 kDa to 36 kDa). 
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Supplemental Figure 5. NUPR1 is present in a majority of 
somatolactotropes. A representative immunofluorescence microscopy image of 
wild-type female mouse pituitary cells that were disaggregated and immuno-
stained for NUPR1, GH, and PRL. Multiple somatotropes (white arrows) can be 
seen which stain strongly for NUPR1, along with a single somatolactotrope 
(GH+/PRL+) (red arrow) that also is positive for NUPR1. Two GH-/PRL- cells are 
also visible which stain much more weakly for NUPR1. In this experiment, a total 
of 50 somatolactotropes (GH+/PRL+) were identified (out of approximately 2000 
pituitary cells imaged) and assayed for NUPR1 expression. Of these 50 
somatolactotropes, 27 (54%) were positive for NUPR1. 
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Supplemental Figure 6. Expression of Pou1f1 in Pit-1/0 cells drives 
productive transcription of Prl as compared with the production of short, 
abortive transcripts from the Gh promoter. A. Schematic of PCR amplification 
strategy to detect short, abortive transcripts. The intron/exon structure of the Gh 
and Prl genes is remarkably similar, and so this five exon schematic represents 
both the Gh and Prl genes as the primer design (orange arrows) approach was 
similar for both genes. A shared forward primer was placed at the transcription 
start site (TSS) and two reverse primers, one 50 bp downstream of the TSS and 
one 100 bp downstream of the TSS were combined with the forward primer to 
analyze abortive transcripts. Exon-spanning primers were designed further into 
the gene body (“gene body” primers) to assay productive, elongated transcripts. 
B. Quantitative RT-PCR was performed using these primer sets in Pit-1/0 cells 
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that had been transfected with plasmids expressing Pou1f1 +/-  Nr4a2. RNA was 
isolated and treated with DNase to eliminate genomic DNA contamination. N = 3 
biological replicates. * indicates a p-value <0.05 while ** indicates a p-value < 
0.01.  
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Introduction 
Having identified a set of transcription factors that are enriched in 
somatotropes and lactotropes and appear to have functional impacts on the 
expression of crucial somatotrope and lactotrope genes, a key challenge was to 
validate these function(s) in the in vivo. Nr4a2, Nupr1, and Pou4f1 were selected 
for further study based on their functional impacts on landmark somatotrope and 
lactotrope genes in the context of our cell line model system (Chapter III). These 
transcription factors may be important regulators of the maintenance of 
somatotrope/lactotrope cell fate in terminally differentiated cells, by enhancing 
landmark genes of a cell lineage, or in reciprocally repressing the landmark 
genes of a divergent lineage. It is crucial to understand the effect these 
transcription factors have on the cell identity of somatotropes and lactotropes in 
the context of primary pituitary cells in order to gain a more complete 
understanding of their mechanisms of action and contribution(s) to the cellular 
composition and hormonal functions of the intact pituitary. 
Given the effects of the two lactotrope transcription factors Nr4a2 and 
Pou4f1 on Prl expression in our cell-based assays, we hypothesized that their 
ablation in the lactotropes of mice might result in a decrease in Prl expression 
and/or a decrease in lactotrope representation in the pituitary. We anticipated 
that impacts of the deletions of these factors might be detected at the cellular 
level by decreases in the number or intensity of PRL+ cells, by decreases in Prl 
mRNA in total pituitary RNA, and/or lactation or maternal activity phenotypes. 
Our cell-based data would predict that deletion of either of these transcription 
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factors would only have a partial impact on Prl expression because Pou1f1 is 
sufficient in the absence of either factor to drive Prl expression to appreciable 
levels (Fig. 6F)92, an observation consistent with studies that have identified 
Pou1f1 as a major activator of Prl expression8,9,21. Thus, mice lacking either 
Nr4a2 or Pou4f1 in lactotrope cells are predicted to maintain an appreciable level 
of Prl expression, albeit at levels lower than those observed in wild-type mice.  
A third transcription factor of interest based on our prior cell-based studies 
is Nupr1. This factor is enriched in somatotropes and appears to be involved in 
the repression of two lactotrope-specific proteins; Prl and Drd2. These data 
suggest that lactotrope-defining genes are under active repression in 
somatotropes and that the deletion of Nupr1 in primary mouse somatotropes 
might therefore result in a de-repression of Prl in the somatotropes. Thus, we 
would predict that mice with a selective ablation of Nupr1 in somatotropes might 
exhibit conversion of a subset of somatotropes to a dual positive state 
(GH+/PRL+).  
We describe in this Chapter a series of studies that were designed to 
validate the roles of the three identified transcription factors in primary 
somatotropes and lactotropes. This was accomplished by obtaining and/or 
generating lines in which the genes encoding each of the three transcription 
factors could be inactivated in a cell-type specific manner. To achieve this goal, 
we crossed mouse lines that selectively express Cre recombinase in either 
somatotropes or in lactotropes with lines in which each of the three target loci 
were flanked by LoxP elements (“floxed” mouse lines). Compound transgenic 
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progeny (Cre x Flox/Flox), were studied to probe the function of each 
transcription factor in the respective cell lineage. Here, we present data from 
these cell type specific knockout mouse lines to demonstrate that two of the 
newly identified somatotrope/lactotrope enriched transcription factors, Nupr1 and 
Nr4a2, have respective repressing and enhancing actions on Prl expression in 
somatotropes and lactotropes within the adult murine pituitary. These 
observations in an in vivo setting are consistent with the activities observed in our 
cell culture-based studies (Chapter III) and provide an expanded understanding 
of somatotrope and lactotrope regulation. 
Results 
Generation and validation of mouse lines that support conditional 
inactivation of targeted transcription factors in the somatotrope or 
lactotrope lineages  
 To generate inactivating mutations of selected transcription factors 
specifically in somatotropes or lactotropes, we needed mouse lines that express 
Cre recombinase under the control of either the Gh or Prl regulatory elements. 
An existing Gh-Cre mouse line that has been validated for expression of Cre in 
somatotropes16 was provided by the lab of Dr. Sally Camper. A corresponding 
Prl-Cre mouse line was not available, so we generated this line by inserting the 
Cre ORF into the second exon of the Prl gene within the context of a 200 kb 
bacterial artificial chromosome (BAC) containing the mouse Prl locus. The BAC 
clone used for this insertion was selected based on its extensive (>50 kb) 
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sequences both 5’ and 3’ of the Prl gene. In the absence of evidence that the 
mPrl gene is under remote regulatory control93, the presence of these extensive 
flanking sequence was assumed to be sufficient to drive lactotrope-specific 
expression (Fig. 13A). The recombinant BAC was generated by standard BAC 
recombineering (see Methods) and was microinjected into B6SJLF1/J mouse 
embryos by the Penn Transgenic Mouse facility94. After establishing a line of 
transgenic mice carrying this Prl-Cre transgene, the mice were crossed with mice 
(provided by Dr. Douglas Epstein) carrying a ZsGreen reporter gene with an 
upstream lox-stop-lox to identify sites of Cre recombinase expression95.  
In order to validate the accuracy of Cre expression from the Prl-Cre 
transgene, we collected pituitaries from mice carrying both the Prl-Cre and 
ZsGreen transgenes (Prl-Cre/ZsGreen). These pituitaries were disaggregated, 
and immunostained for GH, PRL, and ZsGreen using an anti-GFP antibody (Fig. 
13B). 91% of PRL positive lactotropes were also positive for the ZsGreen 
reporter protein, while only 1.1% of all GH positive somatotropes expressed 
ZsGreen (Fig. 13C). These data indicated robust lactotrope specificity for the 
expression of Cre recombinase. This lactotrope-specific Cre line was used along 
with the previously established somatotrope-specific Cre line for the subsequent 
conditional knockout studies16. The specificity of the Gh-Cre mouse line, 
previously described16, was similarly assayed and validated (Supplemental 
Figure 7). 
 Having established mouse lines expressing somatotrope/lactotrope 
specific Cre recombinase, we next focused on obtaining mouse lines carrying 
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floxed alleles of each of the three transcription factors of interest: Nupr1, Pou4f1, 
and Nr4a2. Existing lines carrying floxed alleles of Pou4f1 and Nr4a2 were 
obtained from cooperating labs (the labs of Dr. Tudor Badea96 and Dr. Thomas 
Perlmann97, respectively). We generated the remaining mouse line carrying a 
floxed Nupr1 allele in conjunction with the Penn CRISPR/Cas9 Mouse Targeting 
Core. LoxP elements were inserted flanking exon 2 of endogenous Nupr1 locus. 
The positioning of these LoxP elements was chosen based on previous reports 
that germline deletion of exon 2 is sufficient to abolish NUPR1 activity in the 
mouse98. Together with the somatotrope and lactotrope specific Cre lines, the 
three floxed mouse lines allowed us to selectively delete each transcription factor 
specifically in the somatotrope or lactotrope lineages.  
Deletion of Nr4a2 in lactotropes causes a decrease in prolactin expression 
in mouse pituitary 
 In our preceding studies we demonstrated in a cell line model and in 
primary pituitary cells that the orphan nuclear receptor NR4A2 binds within the 
Prl promoter at a site that is adjacent a known POU1F1 binding site. We further 
demonstrated by transfection studies in the Pit-1/0 cell line that forced expression 
of Nr4a2 enhanced Prl expression in a POU1F1 dependent manner (Fig. 6F)92. 
To validate and extend these findings in vivo, we generated Nr4a2flox/flox; Prl-Cre 
mice and performed immunofluorescence microscopy on disaggregated cells 
from their pituitaries. Control mice that were homozygous for the floxed allele of 
Nr4a2 but negative for Cre recombinase (Nr4a2flox/flox) expressed NR4A2 in 
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nearly all lactotropes (90%, N = 371 PRL+ cells) (Fig. 14A). This percentage of 
lactotropes expressing the NR4A2 protein is consistent with that seen in wild type 
mice (Fig. 4D), confirming that the inserted loxP sites do not affect expression of 
the Nr4a2 gene. In clear contrast, we observed a dramatic decrease in the 
number of cells that expressed NR4A2 in Nr4a2flox/flox; Prl-Cre mice, where 
NR4A2 protein was expressed at detectable levels in only 31% of the PRL+ cells 
(N = 393 PRL+ cells.). These data lead us to conclude that Nr4a2flox/flox; Prl-Cre 
mice exhibit greatly reduced NR4A2 expression in lactotrope cells, confirming 
successful ablation of Nr4a2 in the majority of lactotrope cells. 
 Next, an immunofluorescence study was performed to determine the 
impact of Nr4a2 ablation on PRL expression in mouse lactotropes. De-identified 
slides produced from pituitary cells isolated from littermates with Nr4a2flox/flox or 
Nr4a2flox/flox; Prl-Cre genotypes were stained for GH and PRL. We observed that 
the pituitaries isolated from Nr4a2flox/flox; Prl-Cre mice had approximately half as 
many PRL+ cells as their Nr4a2flox/flox littermates (Fig. 14B) while the numbers of 
GH+ cells and dual GH+/PRL+ cells were not significantly different between these 
two groups. This reduction in PRL expression was paralleled by RT-PCR assays 
of mRNA levels, demonstrating an approximately 40% decrease in Prl mRNA in 
the pituitaries of Nr4a2flox/flox; Prl-Cre mice as compared to littermate controls 
(Fig. 14C). These data suggest that Nr4a2 expression is required for robust Prl 
expression in mice. The marked depletion of NR4A2 in 70% of lactotrope cells 
(Fig. 14A) corresponded to a loss of approximately 50% of PRL positive cells 
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(Fig. 14C), supporting a correlation between the amount NR4A2 ablation and the 
loss of PRL expression.  
Deletion of Nr4a2 in lactotropes leads to the presence of “silent” 
lactotropes in the anterior pituitary. 
The approximately 50% decrease in PRL positive cells observed in the 
pituitaries of mice lacking Nr4a2 in lactotropes may be the result of a loss of 
lactotrope cells in the absence of Nr4a2, leading to a decrease in the number of 
lactotropes in the pituitaries of Nr4a2flox/flox; Prl-Cre mice. However, an alternate 
explanation is that Nr4a2flox/flox; Prl-Cre mice have the same number of 
lactotropes as their Nr4a2flox/flox littermates, but only ~50% of these “lactotropes” 
actively express PRL. In this second model, the deletion of Nr4a2 in lactotropes 
leads to the presence of “PRL-silent” lactotropes, i.e., lactotropes that are 
negative for PRL staining. In an effort to distinguish between these two models, 
we stained the pituitaries of Nr4a2flox/flox; Prl-Cre mice and Nr4a2flox/flox littermates 
for PRL and POU1F1. POU1F1 is expressed in the three Pou1f1 lineages: the 
somatotropes, the lactotropes, and the TSH-producing thyrotropes. Since 
thyrotropes constitute <5% of anterior pituitary cells, while somatotropes and 
lactotropes can range from 30-50% of all anterior pituitary cells1,2, nearly all 
POU1F1 positive cells in the anterior pituitary are either GH-positive 
somatotropes or PRL-positive lactotropes. By staining for these two proteins, we 
would predict that the presence of “PRL-silent” lactotropes could be detected by 
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observing an increase in the amount of POU1F1+/PRL- cells in Nr4a2flox/flox; Prl-
Cre as compared to Nr4a2flox/flox littermates.  
Consistent with this prediction, immunofluorescence microscopy revealed 
an increase in the amount of POU1F1+ cells that do not express PRL in 
Nr4a2flox/flox; Prl-Cre mice, as indicated by a significantly higher ratio of 
POU1F1+/PRL- to POU1F1+/PRL+ cells in their pituitaries (ratio of 4.72) as 
compared to Nr4a2flox/flox littermate controls (ratio of 1.64) (Fig. 15 A and B). This 
observation suggests a reduction of Prl-expressing cells within the pituitaries of 
Nr4a2flox/flox; Prl-Cre mice, but not a loss in the total number of POU1F1+ pituitary 
cells. Notably, a subset of cells that co-express both POU1F1 and PRL (Fig. 
15B, white arrow) can be detected in Nr4a2flox/flox; Prl-Cre mice, suggesting that 
while the number of PRL+ lactotropes has decreased, there is not a complete 
loss of this cell population. This increase in POU1F1+/PRL- cells (Fig. 15C) in the 
pituitaries of mice that have ablated expression of Nr4a2 in their lactotrope cells 
suggests that loss of Nr4a2 does not cause complete loss of the cell population, 
but rather causes a loss of Prl expression in adult lactotropes, rendering them 
PRL-silent lactotropes (POU1F1+/PRL- cells).  
Deletion of the lactotrope-enriched transcription factor Pou4f1 in adult 
mouse lactotropes fails to alter Prl expression 
 Pou4f1 was identified as a second lactotrope-enriched transcription factor 
that had a positive impact on Prl expression when tested in our Pit-1/Triple cell 
line model system (Chapter III)92. These results predict that inactivation of 
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Pou4f1 in the lactotropes of the mouse pituitary would have a negative impact on 
the expression of Prl and/or the number of PRL positive lactotropes. Such 
findings would parallel those observed after conditional deletion of Nr4a2 in 
lactotropes. A comparison of pituitaries from Pou4f1flox/flox; Prl-Cre mice and their 
control Pou4f1flox/flox littermates by targeted RT-PCR confirmed a significant 
reduction in the level of Pou4f1 expression in the pituitaries of Pou4f1flox/flox; Prl-
Cre mice (Pou4f1 mRNA levels at 30% those observed in Pou4f1flox/flox control 
mice). However, the study failed to reveal a corresponding decrease in Prl mRNA 
expression or an impact on any of the assayed landmark somatotrope or 
lactotrope specific genes. Furthermore, a set of parallel IF studies failed to reveal 
any significant differences in the representations of somatotropes and lactotropes 
within the pituitary cell populations (Fig. 16). These in vivo data suggest that 
Pou4f1 does not play a significant role maintaining the expression of Prl in the 
lactotropes or in maintaining the cellular composition of the pituitary when studied 
in adult mice. What remains a possibility is that the impact of Pou4f1 on Prl 
expression in the Pit-1/Triple cell model reflects a role in lactotrope development 
at an earlier developmental stage of the pituitary rather than in terminally 
differentiated lactotropes as previously hypothesized. Such a model can be 
tested in future studies (see Chapter V). 
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Deletion of the somatotrope-enriched transcription factor Nupr1 in mouse 
somatotropes causes ectopic expression of PRL in somatotropes 
While the lactotrope-enriched transcription factors Nr4a2 and Pou4f1 were 
selected for study due to their observed positive effects in enhancing Prl 
expression, the somatotrope-enriched transcription factor Nupr1 was chosen for 
further study based on our data pointing to a role in repressing two landmark 
lactotrope markers, Prl and Drd2, in the Pit-1/Triple cell line92 (Fig. 5A). Such a 
role would predict that the ablation of this locus in the somatotrope lineage might 
result in a de-repression of Prl and Drd2 in the somatotropes, with an increase in 
the number of dual positive (GH+/Prl+) cells in the pituitary. To test this model that 
Prl gene expression is actively repressed in somatotropes by Nupr1, we first 
assayed the impact of a conditional inactivation of Nupr1 in somatotropes of adult 
mice carrying the Nupr1 floxed allele. Pituitaries of Nupr1flox/flox; Gh-Cre mice and 
their Nupr1flox/flox littermates were assayed for Prl mRNA expression by RT-PCR 
(Fig. 17A). We observed that expression of Nupr1 was significantly reduced in 
the pituitaries of Nupr1flox/flox; Gh-Cre mice as compared to their Nupr1flox/flox 
littermates, thus confirming the conditional inactivation of the Nupr1 allele. This 
ablation of Nupr1 resulted in a significant (2.7-fold) increase in Prl levels in the 
pituitary. While this increase in Prl mRNA was consistent with our previous 
observations (Fig. 5A), the parallel impact on the lactotrope-specific gene Drd2 
was not observed. These data obtained from analysis of the whole pituitary are 
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consistent with a repressive function for Nupr1 on the expression of Prl in the 
somatotrope cells. 
To further investigate the impact of Nupr1 in the adult pituitary, we 
assayed the pituitaries of Nupr1flox/flox; Gh-Cre and Nupr1flox/flox mice by 
immunofluorescence microscopy (Fig. 17B) for alterations in the representations 
of the Pou1f1 dependent lineages. Dispersed pituitary cells were stained with 
antibodies against GH and PRL and cells were counted in a blinded manner as 
previously described. These IF studies revealed a significant decrease in the 
number of somatotropes (GH+/PRL- cells) in the pituitaries of Nupr1flox/flox; Gh-Cre 
mice, from 22% of all pituitary cells in Nupr1flox/flox control mice to 14% of all 
pituitary cells in Nupr1flox/flox; Gh-Cre mice (Fig. 17C). Importantly, the decrease 
in the number of somatotropes was matched by a reciprocal increase in the 
number of dual positive GH+/PRL+ cells from 2% in Nupr1flox/flox mice to 9% in 
Nupr1flox/flox; Gh-Cre mice (Fig. 17D). GH+/PRL+ cells, typically classified as 
“somatolactotrope” cells, are rare within wild-type adult mouse pituitaries, 
constituting approximately 1-2% of total cells1,12,13. The increase in the number of 
such cells in Nupr1flox/flox; Gh-Cre to 9% suggests that inactivation of the Nupr1 
gene in somatotropes resulted in de-repression of the Prl gene. This de-
repression led to the appearance of somatotropes co-expressing both GH and 
PRL, a phenotype that is typically categorized as a “somatolactotrope” cell. Thus, 
our cell culture studies and the conditional gene inactivation studies are 
concordant in assigning a repressive function to Nupr1 at the Prl locus in 
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somatotropes. These findings lead us to conclude that landmark gene(s) of the 
lactotrope cell identity (i.e., Prl) must be actively repressed in somatotropes in 
order to maintain somatotrope cell identity in the adult pituitary (summarized in 
Fig. 18). 
Discussion 
 Despite recent advances in understanding the regulation of the 
somatotrope and lactotrope lineages in the anterior pituitary92, many questions 
remain. The three transcription factors that we focus on in these studies, Nr4a2, 
Pou4f1, and Nupr1 were determined, on the basis of cell culture assays, to be 
regulators of Prl. Two of these factors enhance Prl expression in the context of a 
murine pituitary cell line model (Nr4a2 and Pou4f1), while the third factor (Nupr1) 
suppresses expression of both Prl and Drd2. Thus all three of these transcription 
factors are observed to act on Prl gene expression, but are likely to be acting 
through a variety of mechanisms. These data suggest a previously unrecognized 
complexity in the regulation of hormone genes in the somatotrope and lactotrope 
lineages in the mouse pituitary. Knowledge of the mechanisms of action for 
transcription factors involved in enhancing or repressing expression of hormones 
may provide future studies with potential targets for therapeutics in treating 
disorders of the somatotrope/lactotrope lineages. 
  We began these studies by developing transgenic mouse lines that would 
allow us to probe the effect(s) of each transcription factor in the context of 
primary somatotropes and lactotropes in the adult pituitary. While some of the 
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required mouse lines were already available and were generously provided by 
their respective labs (Gh-Cre16,99, Nr4a2flox 97, and Pou4f1flox 96), lines for a 
lactotrope-specific Cre and a Nupr1flox allele had to be generated de novo. A Prl-
Cre line was established using BAC recombineering techniques (see Methods) 
to insert the Cre ORF into the second exon of the Prl gene in the context of a 
BAC containing the region of the mouse genome (~200 kb) containing the Prl 
locus. Mice carrying this transgene were validated for lactotrope specific Cre 
expression (Fig. 13), establishing a lactotrope-specific Cre mouse line to 
complement the existing Gh-Cre mouse line. A Nupr1flox line was generated by 
the CRISPR/Cas9 Mouse Targeting Facility (see Methods) and validated for 
insertion of the LoxP sites via PCR and sequencing. Together, this set of mouse 
lines with floxed alleles and with lineage-specific Cre drivers allowed us to 
explore the in vivo functions of the selected transcription factors and to determine 
their roles in maintaining the somatotrope and lactotrope lineages in the adult 
pituitary. 
Ablation of the lactotrope-enriched factor, Nr4a2, reduces Prl expression in 
a subset of lactotropes  
 We focused our initial studies on the transcription factor Nr4a2. This factor 
enhances Prl expression in the context of a cell line model system by binding to 
the Prl promoter (Fig. 5C)92. The majority of lactotropes (69%, N = 393 PRL+ 
cells) in Nr4a2flox/flox; Prl-Cre mice did not express substantial amounts of NR4A2 
protein as assayed by immunofluorescence microscopy (Fig. 14A). The 
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remaining 31% of lactotropes did express NR4A2, indicating that ablation of 
NR4A2 in these mice is not total, but is substantially reduced in comparison to 
Nr4a2flox/flox littermate controls, where 90% (N = 371 PRL+ cells) express NR4A2. 
Interestingly, we observe a subset of lactotropes in Nr4a2flox/flox; Prl-Cre mouse 
pituitary that is depleted of NR4A2 but still produces PRL (Fig. 14A, right panel).  
The reduction in the number of lactotropes was quantified via blinded 
immunofluorescence microscopy assays to ensure that there were no biases in 
the cell counting (Fig. 14B). Notably, approximately half of the lactotrope 
population persists in the pituitaries of Nr4a2flox/flox; Prl-Cre mice, suggesting that 
although Nr4a2 is an important regulator of the lactotrope lineage, it is not the 
sole determinant of this cell type.  
It is noteworthy that a subset of lactotropes show a complete loss of PRL 
protein expression as assayed by immunofluorescence microscopy, rather than a 
partial loss of PRL expression as initially hypothesized. While further study is 
necessary to determine the cause of the complete loss of PRL expression from 
some lactotropes, one interesting possibility is that there are multiple sub-types 
of lactotrope cells. It is possible that there exists a lactotrope sub-type that 
cannot express Prl in the absence of Nr4a2 while there exists one or more sub-
type(s) that can continue to express Prl in the presence of Pou1f1 alone. The 
existence of such lactotrope sub-types would be consistent with single-cell RNA 
sequencing analysis that shows evidence of multiple sub-populations of 
lactotrope cells within the murine pituitary (Ho et al., In review). Consistent with 
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the detection of a 45% loss of cells expressing the PRL protein, Prl mRNA levels 
are also reduced by approximately 40% in Nr4a2flox/flox; Prl-Cre mice (Fig. 14C). 
Together, these data support the hypothesis that Nr4a2 represents a non-
redundant enhancer of Prl gene expression.  
 To further characterize the loss of PRL expressing lactotropes in 
Nr4a2flox/flox; Prl-Cre mice, we performed immunofluorescence microscopy by co-
staining for POU1F1 and NR4A2. POU1F1 is the primary known activator of both 
Gh and Prl expression and is essential to the development of the somatotrope 
and lactotrope populations21,39. Based on our previous studies, ablation of Nr4a2 
is not expected to impact the expression of Pou1f1 and therefore, even if Prl 
expression is lost, Pou1f1 will remain expressed in lactotrope cells and can be 
used as a marker. The majority of POU1F1 positive cells in the pituitary are 
either somatotropes or lactotropes, with thyrotropes comprising only 5% of the 
total cells1. Thus, co-staining for POU1F1 and NR4A2 in the pituitaries of 
Nr4a2flox/flox; Prl-Cre mice and Nr4a2flox/flox littermate controls can be used to 
detect the presence of “silent” lactotropes: lactotrope cells that express POU1F1 
and other lactotrope proteins, but no longer express PRL due to deletion of a 
transcription factor such as Nr4a2.  
Using this method, ablation of Nr4a2 in lactotropes was observed to cause 
a significant shift in the ratio of POU1F1 positive, PRL negative cells to POU1F1 
positive, PRL positive lactotropes in comparison to the ratio observed in 
littermate controls (Fig. 15). This result suggests that “lactotrope” cells are still 
95 
 
present in the pituitaries of Nr4a2flox/flox; Prl-Cre mice, but that they no longer 
express prolactin. Further study is ongoing to confirm that these POU1F1+/PRL- 
cells are also negative for GH. These data suggest that ablation of Nr4a2 causes 
a loss of prolactin expression in lactotrope cells, rather than an outright loss of 
lactotropes, as evidenced by the increase in POU1F1 single positive cells in 
Nr4a2flox/flox; Prl-Cre mice. Taken together with previous data, this study indicates 
that Nr4a2 likely plays a role in maintaining the expression of Prl in the 
lactotropes of adult mice.  
The lactotrope-enriched transcription factor, Pou4f1, failed to impact Prl 
expression in mice 
In addition to our studies on the role of Nr4a2 in lactotrope cells, we also 
assayed the effect of Pou4f1 in lactotropes with our hypothesis being that Pou4f1 
plays a similar role to Nr4a2 in these cells due to its similar effect on Prl 
expression in previous cell line studies (Fig. 5D). However, both 
immunofluorescence microscopy (Fig. 16A and B) and RT-PCR (Fig. 16C) failed 
to reveal any evidence that Pou4f1flox/flox; Prl-Cre mice have lower levels of Prl 
expression or fewer lactotropes than their Pou4f1flox/flox littermates, although a 
reduction of Pou4f1 mRNA was confirmed, indicating successful ablation of 
Pou4f1. These data contrast with previous data from mouse pituitary cell lines 
(Fig. 5D) and may suggest that Pou4f1 does not play a role in the regulation of 
Prl expression in the lactotropes of adult mice. Conversely, it is possible that 
Pou4f1 plays a role in the regulation of Prl, but there is another gene or genes 
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that are functionally redundant with Pou4f1, such that deletion of Pou4f1 alone is 
not sufficient to impact Prl expression in mice. Alternatively, Pou4f1 may play a 
role in an earlier stage of lactotrope development, prior to Prl expression. Testing 
this possibility would require producing mice that carry both the Pou4f1flox/flox 
allele as well as a Cre recombinase transgene that is expressed at an earlier 
stage of pituitary development than the Prl-Cre used in these studies. 
Development of such mice falls outside the scope of the present study, but is an 
interesting topic for future studies to assay and is discussed further in Chapter V. 
The somatotrope-enriched transcription factor, Nupr1, represses Prl 
expression in somatotrope cells 
In contrast to lactotrope-enriched transcription factors such as Nr4a2 
which enhances Prl expression, we also assayed a somatotrope-enriched 
transcription factor, Nupr1, that our cell based assay suggested has a repressing 
effect on Prl expression (Fig. 5A). Nupr1flox/flox; Gh-Cre mice have fewer 
somatotropes (GH+/PRL-) in their pituitaries than Nupr1flox/flox littermate control 
mice, and demonstrate a robust increase in the representation of GH/PRL dual 
positive cells (Fig. 17). Conventionally, such dual positive cells are identified as 
somatolactotropes and constitute 1-2% of the adult pituitary population1. As 
noted earlier (see Chapter I), the origin of the somatolactotrope cells remains 
ambiguous, with some reports identifying them as precursors to both the 
somatotropes and the lactotropes2 while others hypothesize that they are a 
transitional state between somatotropes and lactotropes13. While a conventional 
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somatolactotrope and a GH/PRL dual positive cell that arises from de-repression 
of Prl expression in Nupr1flox/flox; Gh-Cre mice may appear indistinguishable by 
immunofluorescence microscopy with GH/PRL staining, it should be noted that 
they are not necessarily identical nor are they necessarily generated by similar 
mechanisms. Somatolactotropes may have currently unknown traits or 
transcriptomic differences which distinguish them from the somatotropes and 
lactotropes beyond simply co-expressing GH and PRL. In contrast, the GH/PRL 
dual positive cells observed after deletion of Nupr1 in mouse somatotropes may 
simply be somatotropes that are ectopically expressing Prl with no further 
changes in cell identity, a distinction that will require a better understanding of the 
somatolactotrope cells to resolve.  
While this distinction between somatolactotropes and somatotropes that 
ectopically express PRL may appear minor, it raises a question that has been 
central in the study of anterior pituitary cell types, yet remains incompletely 
answered: how does one define a somatotrope or a lactotrope? Conventionally, 
cells that express GH alone are defined as somatotropes while cells that express 
PRL alone are categorized as lactotropes. This classification paradigm has been 
useful in the study of these cells, but it obfuscates the lack of a deep 
understanding of somatotrope/lactotrope cell identity. As previously discussed 
(Chapter I), there are few genes that can be classified as crucial to the 
somatotrope or lactotrope cell identities beyond the hormone genes themselves, 
Gh and Prl, and receptors for hypothalamic signals such as Ghrhr and Drd2, 
98 
 
respectively. Without knowledge of more genes that are essential to the 
somatotrope/lactotrope identities, it is a challenge to classify these cells in a truly 
meaningful way. Classifying somatotropes/lactotropes purely by their expression 
of the GH or PRL proteins may be sufficient when describing the normal, adult 
pituitary, but it is less useful for studies in which perturbations of transcription 
factors such as Nr4a2 or Nupr1 occur.  
Defining a cell type by its expression of a hormone alone may be 
problematic. For example, if a lactotrope ceases to express PRL, as seen when 
Nr4a2 is deleted (Fig. 13), should it still be classified as a lactotrope? Drd2, while 
enriched in lactotropes, is also expressed in other pituitary cells100, and thus 
cannot be used to classify lactotropes without other identifying marks to 
supplement it. The only method of addressing this problem is to identify more 
genes crucial to the somatotrope/lactotrope cell identities, which has been the 
goal of this work. Only with a more complete understanding of the set of genes 
that make a somatotrope a somatotrope can one deal with classifying cells in 
which the hormones-- currently the only landmarks used to determine cell 
identity-- are perturbed. Thus, while GH/PRL dual positive cells that arise from 
the deletion of Nupr1 may appear identical to the somatolactotropes that are 
observed at low frequencies in wild type mouse pituitaries insofar as they both 
co-express GH and PRL, they may in reality represent two different cell types. 
Further study of the somatotrope, lactotrope, and somatolactotrope cell identities 
will be needed to resolve this dilemma. The work presented here in 
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characterizing the transcriptomes of the somatotropes and lactotropes provides a 
critical resource that will be essential in reaching that goal. 
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Figures and legends 
 
Figure 13. Prl-Cre mouse line produces lactotrope-specific expression of 
Cre recombinase. A. Schematic of Prl-Cre transgene. The Cre ORF was 
inserted into the second exon of the Prl gene in the R23-441I3 BAC via BAC 
recombineering. The transgene preserves approximately 50 kb of upstream and 
downstream sequence flanking the Prl locus to include any previously 
undescribed regulatory elements. B. Immunofluorescence microscopy of 
dispersed pituitary cells from Prl-Cre/ZsGreen mice carrying transgenes for both 
the Prl-Cre and a ZsGreen fluorescent reporter preceded by a lox-stop-lox 
element such that ZsGreen is only expressed in cells that also express Cre 
recombinase. Somatotropes are indicated by red arrows, while lactotropes are 
indicated by white arrows. C. Quantification of somatotropes and lactotropes 
expressing ZsGreen reporter detected in B. 
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Figure 14. Deletion of Nr4a2 in mouse lactotropes causes a decrease in 
prolactin positive cells. A. Representative immunofluorescence microscopy of 
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dispersed mouse pituitary cells from control (left panel) and conditional Nr4a2 
knockout (right panel) mice showing NR4A2+ lactotropes (red arrow) in control 
mice and NR4A2- lactotropes (white arrow) in knockout mice. Staining for PRL is 
shown in red, highlighting lactotrope cells while NR4A2 staining is shown in 
green. B. Quantification of cells counted (N = 1500 cells) in blind study of the 
number of GH, PRL, and GH/PRL positive cells in control and Nr4a2 conditional 
knockout mice. C. Quantitative reverse transcription PCR of RNA isolated from 
whole pituitaries of control and Nr4a2 knockout mice. mRNA levels for 5 
landmark genes for the somatotrope and lactotrope lineages were assayed for 
changes (N=2).  
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Figure 15. Ablation of Nr4a2 causes and increase in POU1F1+/PRL- cells 
and a corresponding decrease in POU1F1+/PRL+ cells. A. Representative 
immunofluorescence microscopy images of dispersed pituitary cells from 
Nr4a2flox/flox control mice. POU1F1, the primary known driver of both GH and PRL 
expression, co-stains with PRL in lactotrope cells (white arrows). B. 
Representative immunofluorescence microscopy images from Nr4a2flox/flox; Prl-
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Cre mice. While POU1F1+/PRL+ are detected, their numbers relative to the 
POU1F1+/PRL- cells (ratios) are significantly lower than in Nr4a2flox/flox littermate 
control mice (* indicates significance of difference of ratios between the two 
mouse genotypes). C. Quantification of immunofluorescence studies from B. N = 
2 mice per experimental group. 
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Figure 16. Conditional depletion of the lactotrope-enriched transcription 
factor Pou4f1 fails to impact on Prl expression in adult mouse lactotrope 
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cells. A. Representative immunofluorescence microscopy images of dispersed 
pituitary cells from Pou4f1flox/flox control mice (left panel) and Pou4f1flox/flox; Prl-Cre 
mice (right panel) exhibiting similar distributions of somatotrope and lactotrope 
cells. Cells were stained with antibodies against prolactin (green) and growth 
hormone (red), with DAPI staining (blue) marking nuclei. B. Representation of 
somatotropes (GH+), lactotropes (PRL+), and GH/PRL dual positive 
somatolactotropes in the pituitaries of Pou4f1flox/flox; Prl-Cre mice and control 
littermates. These data are derived from the IF studies, as shown in A. C. RNA 
expression of hallmark genes in total RNA of whole pituitaries from Pou4f1flox/flox; 
Prl-Cre mice and control littermates. These data were generated by RT-PCR and 
normalized to Gapdh expression. N=2. * indicates p-value <0.05. 
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Figure 17. Conditional depletion of Nupr1 in somatotropes results in an 
increase in Prl expression in the mouse pituitary with a corresponding 
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increase in GH/PRL dual positive cells. A. qRT-PCR of total RNA isolated from 
whole pituitary samples from Nupr1flox/flox; Gh-Cre and Nupr1flox/flox mice. N = 3 
mice per genotype. B. Representative immunofluorescence microscopy images 
of dispersed pituitary cells from Nupr1flox/flox mice, showing a typical distribution of 
GH and PRL single positive cells (somatotropes and lactotropes). Images are 
separated into nuclear DAPI staining (blue), growth hormone (green), prolactin 
(red) as well as a merged image. Somatotropes are indicated by red arrows. C. 
Representative immunofluorescence microscopy images of dispersed pituitary 
cells from Nupr1flox/flox; Gh-Cre mice, showing multiple GH/PRL dual positive cells 
(white arrows). D. Cell counts for GH positive somatotropes, PRL positive 
lactotropes, and GH/PRL dual positive cells observed by immunofluorescence 
microscopy presented as a percentage of total pituitary cells. N = 3 mice per 
genotype, 300 cells counted per mouse.  
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Figure 18. Modified model for selective expression of Gh and Prl in 
somatotropes and lactotropes (based in work in the current thesis). The 
master regulatory transcription factor POU1F1 is present in both somatotropes 
and lactotropes and occupies the promoters of the Gh and Prl genes. The 
actions of POU1F1 at these sites is responsible for base-line expression of both 
hormone genes in both lineages. The selective enrichment of Gh and Prl in their 
respective somatotrope and lactotrope lineages reflects the reciprocal actions of 
transcriptional enhancers and repressors. In somatotropes (left), the robust 
expression of Gh, most likely stimulated via interactions of yet unidentified 
factor(s) (“?”, dashed oval) with POU1F1, is complemented by a reciprocal 
repression of Prl transcription by NUPR1. NUPR1 does not appear to act directly 
on the Prl promoter; whether its repressive activity is linked to direct actions at a 
site in cis to the Prl gene, or via indirect mechanism(s) is yet to be determined. In 
lactotropes (right), Gh expression is postulated to be actively repressed (“?”, 
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dashed oval), while Prl expression is selectively activated by the actions of 
NR4A2. NR4A2 occupancy and activity is dependent on the actions of POU1F1.  
NR4A2 acts in conjunction with an adjacently situated POU1F1 to enhance the 
release of Pol II from the Prl promoter. This release activity allows the extension 
of Pol II into the Prl gene body with consequent production of Prl mRNA.   
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Supplemental Data 
 
Supplemental Figure 7. Validation of Gh-Cre mouse line. A. Gh-Cre mice, 
previously reported16, were obtained from the lab of Dr. Sally Camper. To 
validate the mouse line, Gh-Cre mice were crossed with mice carrying a ZsGreen 
transgene in which the expression of ZsGreen is controlled by a Lox-Stop-Lox 
system such that cells which express Cre will also express ZsGreen. The 
pituitaries of Gh-Cre/ZsGreen mice were disaggregated and stained with 
antibodies against GH to mark somatotropes and against ZsGreen to mark Cre-
expressing cells. Of 200 somatotropes (GH+ cells) assayed, 182 (91%) were also 
positive for ZsGreen, indicating robust Cre expression in somatotrope cells. B. 
The same study was performed co-staining cells for both ZsGreen and PRL to 
mark lactotrope cells. Of 200 lactotropes (PRL+ cells) assayed, 64 (32%) were 
also positive for ZsGreen, consistent with previous reports16. 
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Summary 
The anterior pituitary is composed of multiple cell types that are each 
responsible for the production and regulated secretion of a given hormone. The 
Pou1f1-dependent lineages-- the somatotropes, lactotropes, and thyrotropes-- 
have been shown to be primarily regulated by Pou1f1 with few other factors 
having been identified as part of this process. Here, we generated the first 
transcriptome-wide view of gene expression in murine somatotropes and 
lactotropes, giving an unprecedented view into their differential gene expression 
as well as their many similarities. While our transcriptomic data revealed that the 
somatotropes and lactotropes are overall quite similar cell types—an observation 
that differs from the conventional model of these cells as well-distinguished, 
discrete cell types—there also exist small, but crucial subsets of somatotrope 
and lactotrope enriched genes that contribute to the distinct cell identities of 
these populations. 
Among the sets of differentially expressed genes that we identified in 
somatotrope and lactotrope cells, we selected six transcription factors for further 
study, and narrowed down this list of transcription factors. Using a cell line model 
system, we found that the somatotrope enriched transcription factor, Nupr1, and 
two lactotrope enriched factors, Nr4a2 and Pou4f1, had significant functional 
impacts on the expression of genes that are known to be crucial to the 
somatotrope and lactotrope cell identities. While Nr4a2 and Pou4f1 were 
observed to have a positive regulatory effect on the expression of Prl, Nupr1 
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exerted a repressive effect on the expression of both Prl and another crucial 
lactotrope gene, Drd2, in our cell line model system. These observations 
suggested the existence of transcription factors that are expressed in either the 
somatotrope or lactotrope cells that can influence the expression of genes central 
to cell identity through a variety of mechanisms, both enhancing and repressive. 
We next sought to test the functions of these transcription factors in 
mouse models. After generating or acquiring the required mouse lines carrying 
floxed alleles of each transcription factor as well as transgenes that express Cre 
recombinase in either a somatotrope or a lactotrope specific manner, we 
assayed the impact of ablating these transcription factors in primary mouse 
pituitary. Assays of the ablation of Pou4f1 failed to reveal a functional impact on 
Prl expression as predicted by our cell line model studies, and thus it was 
excluded from further study. Ablation of the somatotrope enriched factor, Nupr1, 
led to ectopic expression of PRL in cells that co-express GH, consistent with the 
prediction that Nupr1 is a repressor of Prl in somatotrope cells. Lastly, ablation of 
the lactotrope transcription factor Nr4a2 caused a loss of approximately half of all 
PRL+ cells in the pituitaries of knock-out mice. This loss was further 
characterized and found to be the result of lactotrope cells ceasing expression of 
Prl rather than a failure of lactotrope cells to develop in earlier stages of pituitary 
development. We focused on Nr4a2 to elucidate the mechanism by which it 
enhances Prl expression. These studies revealed that NR4A2 directly binds to 
the Prl promoter and enhances the release of RNA polymerase II from the Prl 
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promoter. Our in vivo mouse studies, focusing on the subset of three transcription 
factors that were identified by our transcriptomic analyses and validated in the 
cell culture studies, reveal a diversity of actions carried out by transcription 
factors in the somatotrope and lactotrope cells that are essential to maintaining 
cell identity.  
Taken together, the data presented in this dissertation reconfigure and 
expand upon the previous standard model of pituitary cell identity. Pou1f1 acts in 
conjunction with other transcription factors that are enriched in either cell type. 
These transcription factors can exert either enhancing or repressive effects on 
the expression of the Prl gene, and the set of transcription factors highlighted in 
this dissertation is likely to represent only a subset of the factors involved in this 
process. These data suggest that the somatotrope and lactotrope cells are cells 
with highly similar transcriptomes, but the expression of a small set of 
somatotrope and lactotrope genes is sufficient to maintain separate cell 
identities.  
Future directions 
Determination of the mechanism of action of Nr4a2 
 Although progress has been made in determining the mechanism by 
which Nr4a2 increases Prl expression, some questions remain open. An 
outstanding question regarding Nr4a2 is what co-factor(s) are recruited to the Prl 
promoter in order to enhance the release of Pol II. To resolve this question, 
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future studies will utilize co-immunoprecipitation of NR4A2 in transfected Pit-
1/Triple cells (which express endogenous Pou1f1) coupled with mass 
spectrometry. A reciprocal co-immunoprecipitation of POU1F1 will allow analysis 
of the complex at the Prl promoter in the absence of NR4A2 (untransfected Pit-
1/Triple cells). By precipitating NR4A2 along with nearby and/or complexed 
proteins, we will be able to identify additional factors that are recruited in the 
presence of NR4A2, and the use of mass spectrometry will provide an unbiased 
view of these factors. Identified factors will then be the subject of mechanistic 
studies to determine their role in enhancing Prl expression. 
 Another question is whether Nr4a2 impacts other genes beyond Prl. While 
Prl was the only gene affected by the presence of Nr4a2 in our cell based 
studies, these studies assayed a small selection of known somatotrope and 
lactotrope genes in order to establish an initial screening of Nr4a2 functions. It is 
possible that other genes are impacted by Nr4a2 beyond the genes assayed in 
our studies, but their identification would require a broad approach. To identify 
other genes that are impacted by Nr4a2, RNA-seq will be performed on 
Nr4a2flox/flox; Prl-Cre and Nr4a2flox/flox mice. Differential gene expression analyses 
will permit the identification of genes that are impacted by the loss of Nr4a2 
specifically in lactotrope cells, generating a data set that will highlight genes for 
further study and synergize with the above Co-IP experiments to provide a better 
understanding of the role of Nr4a2 in lactotropes and the full impact of the loss of 
Nr4a2 on the lactotrope population. 
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Determination of the mechanism of action of Nupr1 in somatotropes 
 Unlike Nr4a2, the potential mechanism of action of the somatotrope-
enriched factor Nupr1 is not currently understood. ChIP of NUPR1 has 
unfortunately not been feasible due to a lack of ChIP grade antibodies and 
known NUPR1 binding sites to serve as positive controls, and thus it is not 
known at present if NUPR1 binds the Prl promoter. Future studies will take a 
genome-wide approach to identifying targets of Nupr1 regulation by performing 
RNA-seq experiments comparing gene expression in somatotrope-specific Nupr1 
knockout mice to floxed control mice in order to identify genes impacted by 
Nupr1 expression in somatotropes. Genes that are identified as being 
differentially expressed in the absence of Nupr1 will be assayed for a role in 
repression of Prl using cell line models. 
 Although ChIP of NUPR1 is not currently feasible without knocking an 
epitope tag into the endogenous mouse Nupr1 locus, changes in chromatin 
modifications at the Prl promoter can be assayed in the presence and absence of 
Nupr1. Pit-1/Triple cells expressing Nupr1 exhibit a repression of both Prl and 
Drd2 expression, which may be the result of repressive chromatin marks such as 
H3K27me and/or H3K9me at the promoters of these genes. This possibility will 
be assayed by comparing the H3K27me profiles at the promoters of Prl and Drd2 
in Pit-1/Triple cells in the presence and absence of Nupr1 expression. An 
increase in repressive chromatin marks when Nupr1 is expressed would indicate 
that Nupr1 operates by in some manner recruiting these histone marks to the 
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promoters of the genes it represses, giving an insight into the mechanism by 
which Nupr1 represses Prl expression in mouse somatotropes. 
 Characterization of impact(s) of identified transcription factors in earlier 
stages of pituitary cell development 
  As previously discussed, conditional deletion of Pou4f1 using a Prl-Cre 
mouse line did not yield any impact on Prl expression in mice (Chapter IV) 
despite an observed impact on Prl expression in Pit-1/Triple cells (Chapter III). 
One possible explanation for this discrepancy is that Pou4f1 acts on the 
lactotrope lineage at a developmental stage prior to Prl expression, and thus the 
Prl-Cre is expressed too late to trigger an effect in Pou4f1flox/flox; Prl-Cre mice. 
This problem could be further investigated in future studies through the use of a 
Cre recombinase under the regulatory control of a gene expressed prior to Prl, 
such as Pou1f1. As the required mice carrying floxed alleles for Pou4f1, Nupr1, 
and Nr4a2 are all established in the lab, this study can be expanded to all three 
transcription factors of interest. Conditional deletion of Pou4f1 in mice carrying a 
Pou1f1-Cre recombinase will be assayed for a reduction in either the number of 
lactotropes, or the level of Prl expression in the lactotropes. Conditional deletions 
of the remaining transcription factors, Nr4a2 and Nupr1 in Pou1f1-Cre mice will 
be assayed for any changes in their established impacts on lactotrope and 
somatotrope cells, respectively, when deleted at an earlier stage in pituitary 
development. These studies will provide a better understanding of how the 
transcription factors identified in this thesis function in the anterior pituitary. 
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Materials and Methods 
Cell and transgenic mouse lines. Mice carrying the previously described 
Gh-GFP and Prl-DsRed transgenes were mated to generate compound 
transgenic mice carrying both reporter constructs (GFP+/DsRed+)45,46. Mice 
carrying the previously described Gh-Cre16 or the newly generated Prl-Cre alleles 
were crossed with either the existing Nr4a2flox 97, existing Pou4f1flox 96, or the 
newly generated Nupr1flox alleles to generate the appropriate conditional 
knockout mice for the described studies. All mice were of a hybrid CD1 x 
B6SJLF1/J background, and were aged to 6-8 weeks before use in experiments 
to allow for the complete maturation of the pituitary gland. All mice used in these 
studies were virgin females. All mouse studies were reviewed and approved by 
the University of Pennsylvania Laboratory Animal Use and Care Committee. The 
Pit-1/Triple and Pit-1/0 cell lines, previously described28, were cultured in 
Dulbecco's modified eagle medium (DMEM) (Life Technologies) plus 10% fetal 
bovine serum (FBS) along with 1× antibiotic-antimycotic solution (Invitrogen). 
Cells were removed from plates for the purposes of passaging and for harvesting 
using a 0.05% Trypsin-EDTA solution (Life Technologies). 
 Generation of transgenic mouse lines. The existing GH-GFP mouse 
line45, provided to our lab as a cosmid containing the GH-GFP transgene, was 
modified with sub-cloning techniques. Briefly, an MluI digestion of the GH-GFP 
cosmid released a fragment containing the GFP ORF as well as upstream and 
downstream Gh sequence. This fragment was sub-cloned into a vector (pGEM-4) 
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and inverse PCR was performed using primers that flanked the sequence 
corresponding to the first 24 amino acids of GH such that only the first 8 amino 
acids would be preserved in the PCR product. This PCR product was then 
ligated to form a plasmid containing a truncated version of the GH-GFP 
sequence that contains only 8 amino acids of GH prior to the beginning of the 
GFP sequence. Such a truncation has been previously demonstrated to ablate 
the secretion of the linked protein45. Lastly, the plasmid was again digested with 
MluI to release the modified Gh-GFP and ligated back into the full length cosmid 
from which it was extracted. This cosmid was then linearized and microinjected 
into mouse embryos by the Penn Transgenic Mouse Facility and Gh-GFP lines 
were established.  
The Prl-Cre transgenic mouse line was generated via a previously 
described BAC recombineering method94. Briefly, a shuttle vector containing the 
Cre ORF flanked by 500 bp of sequence homologous to the desired insertion site 
(the beginning of exon 2 of the Prl ORF) in the mouse Prl locus was generated 
with conventional sub-cloning techniques. Then, bacterial cells were co-
transformed with the shuttle vector as well as the RP23-441I3 BAC, obtained 
from the BACPAC repository. This BAC contains the mouse Prl locus as well as 
over 50 kb of upstream and downstream sequence. Co-transformed cells were 
grown in selective media and screened for co-integrates. After obtaining shuttle 
vector/BAC co-integrates, a second round of selection was performed to select 
for resolution of the co-integrate. Resolved BACs containing the Cre ORF in the 
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proper site within the BAC were confirmed by PCR and pulse field gel analysis. 
Prl-Cre BAC DNA was linearized by restriction enzyme digestion, purified by gel 
extraction, and provided to the Penn Transgenic Mouse facility for microinjection 
into mouse embryos. Prl-Cre mouse lines were confirmed by genotyping after 
birth and proper function of the Prl-Cre transgene was validated by crossing the 
Prl-Cre mouse line with a previously described reporter line. The Nupr1flox mouse 
line was generated by the Penn CRISPR/Cas9 Mouse Targeting facility using 
conventional CRISPR/Cas9 methodologies to target LoxP sites flanking the 
second exon of the Nupr1 locus, as deletion of this exon has been previously 
reported to successfully ablate NUPR1 activity98. 
Fluorescence activated cell sorting. Pituitaries from female 
GFP+/DsRed+ mice were harvested at 6-8 weeks and dissociated mechanically in 
enzyme free cell dissociation buffer (Life Technologies) before being passed 
through a 40 μm filter into DMEM + 10% FBS culture media and centrifuged at 
1000 g for 5 minutes. After centrifugation, cells were resuspended in PBS + 0.1% 
BSA and layered onto a PBS + 4% BSA cushion and centrifuged a second time 
at 100 g for 5 minutes to remove cell debris. Cell pellets were resuspended in 
PBS + 0.1% BSA, 1 μg of DAPI was added directly to the samples, and the cells 
were sorted on a FACS Aria II platform (BD Biosciences) directly into Trizol LS 
reagent (Thermo Fisher Scientific). The cell sorting was performed by the Flow 
Cytometry & Cell Sorting Facility at University of Pennsylvania.  
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RNA isolation and RNA-sequencing. RNA from FACS sorted cells was 
isolated (Trizol LS protocol; Thermo Fisher Scientific) using 10 µg of GlycoBlue 
coprecipitant (Thermo Fisher Scientific) as a carrier. RNA quality and 
concentration were assayed using the RNA 6000 Pico kit (Agilent) with a 2100 
BioAnalyzer (Agilent) platform. High quality RNA samples, defined by RIN scores 
of >7, were submitted to the University of Pennsylvania Next Generation 
Sequencing Core (NGSC) for analysis. Each sample was amplified using the 
Ovation ultralow RNA-seq library system (Nugen) and libraries were sequenced 
on the HiSeq 2500 platform (Illumina). Sequencing data was mapped and 
analyzed by the Penn Next-Generation Sequencing Core (NGSC). GEO 
accession number for sequencing data: GSE118863. 
Cell transfection assays. The cDNA of Nupr1 was amplified from mouse 
pituitary cDNA, and cDNAs for the other studied transcription factors were 
obtained from OriGene or Addgene and sub-cloned into an IRES GFP vector 
(Addgene plasmid #51406). The expression of the cDNA and GFP in this vector 
is controlled by the CMV promoter. Pit-1/Triple and Pit-1/0 cells were transfected 
with 10 μg of plasmid using the TransIT-293 transfection reagent (Mirus Bio). In 
co-transfection assays, cells were transfected with 5 µg of each plasmid to 
maintain the DNA: TransIT-293 ratio as recommended by the manufacturer. Two 
days after transfection, GFP+ cells were FACS sorted using the method and 
platform described above. RNA was isolated from the GFP+ cells as described 
above and cDNA was generated using the SuperScript III reverse transcription kit 
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(Life Technologies). Quantitative real time PCR was performed using the Fast 
SYBR Green Master Mix kit (Applied Biosystems) on a QuantStudio 7 Flex 
(Applied Biosystems) platform. qRT-PCR assays were done in biological 
triplicate, and all samples were normalized to the housekeeping gene Gapdh, 
and compared to cells transfected with an empty vector by the ΔΔCt method 101. 
All transfections were performed using approximately 1.6 million cells per 
sample, grown to 80% confluence in 10 cm plates. Amplification primer 
sequences: Gh: 5’-gcccaggctgctttctgc-3’ and 5’-caattccatgtcggttctctgc-3’. Prl: 5’-
aggggtcagcccagaaagc-3’ and 5’-tcaccagcggaacagattgg-3’. Pou1f1: 5’-
aggtgggagcaaacgaaagg-3’ and 5’-gctccccgaagtgtctctcc-3’. Ghrhr: 5’-
tcacttcggctcagcacagg-3’ and 5’-ggcaagccacagggtatgg-3’. Drd2: 5’-
tgaacctgtgtgccatcagc-3’ and 5’-gacagtaactcggcgcttgg-3’. Gapdh: 5’-
agcttaggttcatcaggtaaactcagg-3’ and 5’-cgttcacaccgaccttcacc-3’. Nr4a2: 5’-
gatcagtgccctcgtcagagc-3’ and 5’-gtcagggtttgcctggaacc-3’. Nupr1: 5’-
gcgggcatgagaggaagc-3’ and 5’-gctgggtgtggtgtctgtgg-3’. Rxrg: 5’-
aagtttcccaccggctttgg-3’ and 5’-gtggctgtccattggcttcc-3’. Pou4f1: 5’-
agtacccgtcgctgcactcc-3’ and 5’-gtccaggctggcgaagagg-3’. 
Immunofluorescence microscopy. Pituitaries were disaggregated and 
prepared using the same process as noted above for FACS. The 
immunofluorescent staining was performed as previously described102. Briefly, 
the disaggregated cells were placed on Poly-L-lysine coated slides and 
incubated at room temperature for 10 minutes to allow the cells to adhere to the 
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slide. After attaching to the slides, cells were fixed in 4% formaldehyde for 10 
minutes, then washed three times with PBS for 5 minutes per wash. Cells were 
permeabilized in a solution of 0.5% triton X-100 and 0.5% saponin for 10 
minutes. The cells were washed with PBS before being incubated in a blocking 
buffer of 4X SSC, 2% BSA, 0.1% Tween 20, and 15% donkey serum for 20 
minutes at room temperature. After blocking, slides were incubated with 
antibodies specific to proteins of interest for 1 hour at room temperature, washed 
three times in PBS, then incubated for one hour at room temperature with 
secondary antibodies conjugated to fluorophores for detection. After incubation 
with secondary antibodies, the slides were washed a final time, incubated for 1 
minute in 1mg/ml DAPI, and cover slips were attached. Slides were imaged with 
a Leica SP8 confocal microscope platform. Images were analyzed using Fiji 
software103. Antibodies used for each transcription factor are as follows: NUPR1 
(Thermo-Fisher PA5-65826, RRID: AB_2662159104), RXRG (Santa Cruz SC-
514134, RRID: AB_2737293105), TBX19 (Santa Cruz SC-22656, RRID: 
AB_2200381106), PPARG (Abcam 55296, RRID: AB_944767107), NR4A2 (Abcam 
ab41917, RRID: AB_776887108) and POU4F1 (Abcam ab81213, RRID: 
AB_1640222109). 
Chromatin Immunoprecipitation (ChIP). ChIP assays were performed 
as previously described110. Chromatin was isolated from approximately 200,000 
FACS sorted transfected cells per sample and chromatin from 100,000 cells was 
used per ChIP reaction. For the purposes of performing ChIP assays, Pit-1/0 
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cells were transfected with 20 µg of plasmid DNA using Lipofectamine 3000 
(Thermo Scientific) per the manufacturer’s directions to achieve higher 
transfection efficiency. Antibodies specific for NR4A2 (Abcam ab41917, RRID: 
AB_776887) and POU4F1 (Abcam ab81213, RRID: AB_1640222) were used in 
the respective assays. H3K27ac ChIP was performed using antibody ab4279 
(RRID: AB_2118291111) and H3K4me4 ChIP was performed using antibody 
ab8580 (RRID:AB_306649). A rabbit antibody specific for POU1F1 was 
generated by Alpha Diagnostics (RRID: AB_2732812112) using the antigen 
sequence: PLLAEDPAASEFKQELRRKSKL. This affinity purified antibody was 
demonstrated to be specific for POU1F1 by Western blot analysis 
(Supplemental Figure 2). Normal rabbit IgG (Millipore) was used as a control in 
all ChIP assays. Input and bound DNAs were amplified by qRT-PCR using the 
same QuantStudio 7 Flex platform noted above. A serial dilution of the input 
chromatin was used to determine the linear range of the amplification and the 
enrichment of the bound DNA was calculated as a percentage of the input. ChIP 
of primary mouse pituitary cells was performed using the same protocol, with 
cells being collected by FACS as above prior to isolation of chromatin. 
Amplification primer sequences: Gh promoter: 5’-gccttggggtcgaggaaaac-3’ and 
5’-gggatttgcgcatgcttacc-3’. Prl upstream control: 5’-gaactggaagctgttgaacttgc-3’ 
and 5’-ggtcttgggaactgaacttgg-3’. Prl promoter: 5’-tggccaatgtcttcctgaatatg-3’ and 
5’-cactggctttataaacctttgaca-3’. Prl downstream control: 5’-
catgcattctaccaaaagggtagg-3’ and 5’-tgcatctctatagcacttggtttatcc-3’. MyoD 
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promoter: 5’-gcgtatggctgccagtctct-3’ and 5’-tgtagtagggcggagcttgg-3’. Pou4f1 
enhancer: 5’-cgcgaaaccaacaaagagttttc-3’ and 5’-ctgtagcgcgtttaaataaatgaagtg-3’. 
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